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Pharmaceutical expenditure is rising in high-income countries. Some countries 
choose to pass some of these costs on to patients through various cost-sharing 
strategies. In many countries, patients pay an out-of-pocket cost for prescription 
medicines. Out-of-pocket costs vary between different countries, the medicines 
being used and the patient themselves. Out-of-pocket costs for medicines can 
represent a significant financial burden for some patients. 
 
Aim 
The aim of this thesis is to examine the costs of prescription medicines incurred by 
patients in a variety of high-income Organisation for Economic Co-operation and 
Development (OECD) countries.  
 
Methods 
A series of model patient scenarios were used to demonstrate the cost of 
prescription medicines as a proportion of patient income. The model patients were 
placed in one of six countries; Australia, Canada, England, Finland, Germany or 
New Zealand. The model patients had a range of ages, income types, and medical 
conditions. The medical conditions included were; asthma, type 2 diabetes 
mellitus, schizophrenia and metastatic renal cell carcinoma. The prescription 
prices paid for medicines by each model patient were then compared using 
purchasing power parities. 
 
Results 
The proportion of income spent on prescription medicines by the model patients 
ranged from 0% to over 50%. Patients with the lowest incomes spent 
proportionally more of their income on the same medicines compared with high-
income patients. Some of the model patients were exempt from prescription 
charges depending upon their age, medical condition or income type. Patients in 
Canada generally paid more than any of the other countries, while patients in 







This is the first study to compare prescription charges for patients across a range 
of countries, patient income types and medical conditions. There was considerable 
variation in patient out-of-pocket costs for medicines across the countries and 
conditions included. The co-payment systems used for prescription medicines in 
each country had many advantages and disadvantages for patients. The study was 
somewhat limited by missing data from some countries. Further research using 
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Co-insurance A type of variable co-payment 
Co-payment The amount a patient pays towards goods or services, with an 
insurer or government agency paying the remainder. The amount a 
patient contributes may be fixed, or variable 
Deductible A fixed amount up to which a patient must pay part of the cost or 
the full cost of prescription medicines 
Dispensing fees The portion of a prescription charge that pays for pharmacy 
services 
Formulary A list of medicines 
Generic medicine A generic medicine is a copy of a medicine made by a company that 
did not develop the drug themselves 
Generic substitution Substituting a generic medicine for a branded medicine 
List prices The prices of medicines agreed to by price regulators or agencies 
that purchase medicines on behalf of the public 
Out-of-pocket (OOP) 
payment/cost 
The patient contributions towards goods or services that will not 
be reimbursed by an insurer or funding agency 
Prescription charges The amount a patient must pay to collect a prescription 
Price regulator An agency that sets the list prices of medicines 
Purchasing power 
parities 
Price relatives showing the ratio of the prices in national 
currencies of the same good or service in different countries 
Reference pricing Grouping together pharmaceuticals with similar effects or the same 
effect and setting the price for the whole group to that of the 
medicine with the lowest price 
Subsidy The proportion an insurer or funding agency will pay for a 
commodity such as a medicine 
Tendering processes A process where pharmaceutical suppliers to provide pricing 




The costs associated with providing healthcare present a huge burden for health 
systems, governments and the general public.(1, 2) Health expenditure is rising in 
high-income countries. This is due to multiple factors, including aging populations, 
increased chronic illnesses and obesity, increased use of new health technologies 
and increased pharmaceutical expenditure. For example, in the United States of 
America (USA), healthcare costs have increased faster than the rate of inflation 
between 1960 and 2013.(3)  
In New Zealand, public spending on health has risen substantially. In 1995, the 
percentage of gross domestic product (GDP) spent on healthcare was 6.95%.(4) By 
2015, that figure had risen to 9.41%. This is a similar increase in health spending 
over the last 20 years to most other countries in the Organisation for Economic Co-
operation and Development (OECD).(4) Current projections by the New Zealand 
Treasury estimate that New Zealand will be spending 10.8% of GDP on healthcare 
by 2060 if increases in healthcare expenditure persist.(5) Similar projections in 
spending have been forecast for other OECD countries.(4)  
The price of pharmaceuticals contributes to increased healthcare expenditure.(2) 
As costs for healthcare increase, some of the costs will be directly incurred by 
patients. In many developed countries, patients already contribute directly or pay 
“out-of-pocket” (OOP) payments towards goods and services such as prescription 
medicines and doctors’ fees.(2) As with healthcare costs, pharmaceutical 
expenditure is increasing faster than economic growth.(2) In OECD countries, the 
proportion of health spending on pharmaceuticals ranges between 6.7% 
(Denmark) to 30.2% (Hungary) (2014).(6) Most of the expenditure is on 
prescription medicines, which are used both in and out of hospital. How 
pharmaceuticals are paid for varies markedly between different countries.(2)  
This thesis examines the costs associated with pharmaceutical expenditure that 
are incurred by patients in public healthcare systems. A group of model patients is 
used, with different ages and levels of income to demonstrate the proportion of 
income patients may have to spend on prescription medicines. The model patients 
are then placed in different high-income countries, with different medical 
conditions, to give examples of what patients might pay for prescription medicines 
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in various scenarios. This gives real-life settings of the prescription costs patients 
face, and allows comparisons between the selected countries. Few studies have 
compared patient prescription charges between countries, for multiple medical 
conditions and different patient types, or investigated these charges in relation to 
proportion of income spent on medicines. It does not investigate the direct impact 
of patient costs for prescription medicines, or the health outcomes for patients 
choosing to use prescription medicines. High-income countries with some level of 
prescription drug coverage are focused on for the purposes of this research. 
 
Approaches to paying for pharmaceuticals 
The simplest method is user-pays. In this, the consumer or patient will pay the full 
cost of obtaining a prescription medicine.(7) Over-the-counter medicines are 
usually paid for in this way.(2) However, in most OECD countries, patient 
prescription medicines costs are usually off-set by public funding of 
pharmaceuticals or private insurance schemes.(2) The coverage provided for 
prescription medicines varies widely between different countries and the types of 
schemes used to pay for pharmaceuticals. Where public coverage is available, some 
form of price regulation by the institutions responsible for pharmaceuticals is 
often in place.(2) 
Most public coverage of prescription medicines is funded through general 
taxation.(8) Social insurance schemes may also be used, where employees or 
employers on behalf of their employees make contributions to an insurance 
scheme which includes drug coverage.(7) Patients may also turn to private 
insurers for drug coverage.(8) 
Cost containment methods 
Cost containment methods used by price regulators include the use of generic 
medicines, reference pricing and formularies.  
A brand name or innovator medicine is a new medicine, which has been developed 
by a particular pharmaceutical company. A new medicine is developed under 
patent protection, but there will be a patent expiry date, after which other 
pharmaceutical companies are able to copy the innovator medicines.(9, 10) These 
copies are called generic medicines. They are tested to make sure that the chemical 
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structure is identical to the innovator medicine and that the clinical effects are the 
same (bioequivalence).(9, 10) The research and development costs associated with 
the production of generic medicine are lower than that of an innovator medicine. 
This means that companies offering generic medicines are usually able to do so at a 
lower price than the innovator medicine.(9) There may also be several 
pharmaceutical companies producing the same generic medicine, which increases 
competition and thus lowers prices.(9) In countries where generic substitution of a 
medicine is allowed, price regulators are able to use tendering processes to 
encourage lower prices.(2) 
Reference pricing is often used in conjunction with generic medicines. Reference 
pricing groups together pharmaceuticals with similar effects or the same effect.(2, 
11) This could be for a single generic medicine (for example, salbutamol), or for all 
the medicines belonging to a particular therapeutic group (such as statins).(2) 
Whichever pharmaceutical has the lowest price will then set the benchmark for the 
other medicines, forcing pharmaceutical manufacturers to provide medicines at 
lower prices.(2)  
A formulary is a list of medicines. In this context, a formulary may be used by a 
price regulator to define a list of medicines for which there is some form of 
coverage available to help patients pay for prescription medicines.(2) This helps to 
limit the number of medicines which are to be funded by a plan. Usually this is a 
“positive” list, meaning that all prescription medicines on the list will be covered in 
some way. Alternatively, there may be a “negative” list, where anything on the list 
will not be funded, and all other available prescription medicines will have some 
degree of coverage.(2) 
Cost-sharing strategies 
Most OECD countries have some form of cost-sharing strategy for prescription 
medicines.(2) Countries may also use several cost-sharing strategies in concert. 
There may be some benefits in patients contributing to the cost of pharmaceutical 
products, for example, discouraging the use of unnecessary medicines and 
medicines waste.(12, 13) Cost-sharing is also another cost-containment 
method.(14) However, for many patients, contributing to pharmaceutical costs is a 
barrier to receiving effective treatment.(15, 16)  
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Types of cost-sharing  
Co-payments 
Co-payments are one of the most common forms of cost-sharing. The incentive to 
use co-payments may be to give patients insight into the cost of their 
medicines.(15) There are two main types of co-payment, fixed co-payments and 
variable co-payments. Fixed co-payments are a fixed price per item per 
prescription.(12, 17) With variable co-payments, patients usually pay a percentage 
of the prescription cost, with the insurer or funder paying the remainder.(12, 17) 
This is also known as “co-insurance”.(18) What percentage is paid may depend on 
the patients’ medical condition/s, whether the medicine is an innovator or generic 
medicine, or how essential the medicine is (life-saving medicines will usually have 
a lower patient co-payment).(12, 17) When variable co-payments are used, the 
original price for the medicine paid for or negotiated by the funding agency also 
becomes a factor. This means that if a funding agency has paid a high price for a 
medicine, the patient, through the co-payment will also be paying more. Reduced 
co-payments may also be available for patients on low-incomes or receiving 
government benefits.(17) 
Contribution limits 
Many schemes have a maximum contribution limit or “safety net”.(2, 17) Before 
reaching the contribution limit, a patient may be responsible for all or part of the 
medicine cost. Once a patient or their family has reached this limit, the patient will 
pay nothing, or a minimal co-payment for access to any further medicines 
needed.(2) Usually, contribution limits are for one year’s pharmaceutical 
expenditure.(2) Some contribution limits may be targeted to more vulnerable 
populations, such as the elderly.(2, 17)    
Deductibles 
A deductible is a fixed amount up to which a patient must pay part of the cost or 
the full cost of prescription medicines.(17) Deductibles are often combined with a 
fixed or variable co-payment.(12) Once the deductible amount is reached, the 
required co-payments are lower.(12)   
All of these types of cost-sharing may also be influenced by other factors, such as 




Why people are vulnerable to health costs? 
Accessing healthcare can be difficult for patients for many reasons, including 
distance to services, especially for patients living in rural areas, and language 
barriers. A considerable factor is that the direct cost to patients may delay or 
restrict a patient’s access to healthcare.(15) Some patients may find it particularly 
difficult to meet these direct or OOP costs, including those for prescription 
medicines.  
Who is most vulnerable to health costs? 
People most vulnerable to health costs include; those who are unemployed or have 
low income, the elderly, children under 5 years, those with chronic medical 
conditions and those unable to work due to illness or disability.(2, 19)  The design 
of the health coverage system also impacts who the most vulnerable people are, for 
example, in some systems children or the elderly are exempt from health costs.(8) 
For pharmaceutical product costs, the main OOP costs patients face are those 
related to obtaining a prescription from a prescriber and costs for collecting a 
prescription from a pharmacy (prescription charge).(14) Patients who have 
multiple medical conditions, or comorbidities often need to take many medicines. 
This places a considerable financial burden on patients if they are required to 
make an OOP payment for each medicine, potentially all at one time. The model 
patients used in the thesis help to show which groups of patients are more 
susceptible to prescription costs, and which patients are likely to have high costs 
relative to their income. 
Indigenous peoples’ access to healthcare 
Health disparities are often present between indigenous people and the rest of a 
country’s population.(8) Australia, Canada and New Zealand all have indigenous 
populations with lower life expectancies than the rest of the population.(8) In New 
Zealand, Māori patients are less likely to be able to afford prescription medicines 
than New Zealand Europeans.(20) In Australia and New Zealand, there are some 
regional health programmes aimed at reducing health disparities.(8) Canada is the 
only country of these three with a specific programme for prescription drug 




What happens when people cannot pay for their medicines 
Previous studies have explored the ways patients may mitigate or reduce the costs 
of their medicines.(16, 22) The methods patients may use include; going without 
food, taking a lower dose of a prescribed medicine to make the supply last longer, 
only collecting part of a prescription, delaying collection of medicines until money 
is available, buying a cheaper over-the-counter (OTC) product and not collecting 
their medicines at all.(16, 22) At an individual level, this behaviour will have a 
detrimental effect on a patient’s health, either by depriving them of life’s essentials, 
receiving sub-therapeutic doses of medicines, or missing out on a medicine. Not 
taking a medicine as prescribed, or going without basic necessities, may result in 
poorer health outcomes and increased use of secondary care services.(18, 23) In a 
survey of people with cardiovascular disease, those people who reported not 
taking all their medicines as prescribed (due to cost), were more likely to be 
hospitalised in the next two years.(24) Another study, of patients with chronic 
obstructive pulmonary disease, reported people going without medicines and 
medical services due to financial hardship. As a result, people had to use savings or 
take out loans to meet financial obligations.(25) 
In the wider population, patients not taking their prescribed medicines has further 
implications for healthcare-related costs. For some people with chronic medical 
conditions who might not take their medicines, their condition may exacerbate, 
which may result in days off work and more hospital admissions.(26) This has 
economic implications, such as, the loss of productivity for workplaces, and the 
increased healthcare costs associated with deterioration of their condition and 
subsequent hospital care.(26)  
While this thesis focuses on the amount patients pay for medicines when they are 
collected from a pharmacy, it is important to remember that there may be other 
costs associated with obtaining medicines. This includes, but is not limited to; 
doctors’ fees, the cost of associated over-the-counter medicines, and private 
insurance costs. In this thesis, only public coverage is investigated, with the 
assumption that patients with additional private insurance will generally absorb 




Profiles of countries to be included in the study 
The countries chosen for this study are Australia, Canada, England, Finland, 
Germany and New Zealand. Population and spending information data for each 
country is outlined in Table 1. These countries are high-income countries with 
universal health coverage for secondary care and above.(8) However, there is 
more variation in health coverage in primary care and often prescription medicine 
costs may not be fully covered. 
 
Table 1. Population and health spending data for countries included in the study 























































































































































Further detail of the rationale for choosing these countries is in the Methods 
chapter. Each country’s healthcare system and funding for pharmaceuticals will be 
briefly introduced here. 
 
Australia 
Australia’s healthcare is mostly publicly funded through general taxation.(8) 
Australia’s governmental system is made up of a federal government and state 
governments. Most of the funding for healthcare is provided by the federal 
government through general taxation.(8) Meanwhile the states have the 
responsibility of providing services to patients.(8) Treatment in hospitals is free 
and there are subsidies for most medical services, including prescription 
medicines.(30) Private hospitals and services are available, though access to 
private care requires either OOP payments by patients or for patients to pay for 
private health insurance. 
 
The Pharmaceutical Benefits Scheme (PBS) subsidises the cost of medicines for 
most Australians.(31) Medicines that are subsidised are listed in the Schedule 
(Australia’s version of a formulary). Medicines that are not on the Schedule may be 
prescribed, but the patient must pay the full cost. However, more than 90% of 
prescriptions are covered by the PBS.(30) New medicines are added to the PBS 
after assessment by the Pharmaceutical Benefits Advisory Committee (PBAC).(30) 
The PBAC is made up of a group of health professionals, economists and consumer 
representatives. They examine clinical effectiveness, safety and cost-effectiveness 
of new medicines.(32) 
 
A co-payment for a prescription medicine is required at the time of dispensing.(32) 
One month’s supply of an item is usually dispensed.(33) For most patients, the co-
payment can be up to $37.70 AUD per item(2015).(34) The co-payment will be 
reduced if the original price of the medicine is less than  $37.70 AUD. For patients 
with a concession card the co-payment is $6.10 AUD per item (2015).(34) People 
eligible for a concession card include those receiving some government benefits, 
those on low incomes, those over 65 years of age, and veterans.(35) For non-
concession patients, the maximum amount to pay (the “Safety Net”) for PBS 
prescription medicines annually is $1453.90 AUD (2015), after which co-payments 
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are at the concession card rate.(34) For concession card patients, the “Safety Net” 




Canada’s publicly funded healthcare system (Medicare) covers most hospital and 
physician services for Canadian residents.(36) Healthcare in Canada is funded 
through general taxation at both the federal and provincial levels.(8) The federal 
government regulates and helps to fund Medicare. Provinces and territories in 
Canada are responsible for providing and managing healthcare services to their 
residents.  Each province/territory has its own public healthcare plan and 
residents who are insured through their home province/territory plan have access 
to healthcare anywhere in Canada.(36) Each of the provinces included in this study 
will be considered separately, as each province has its own public plan. This is 
different to Australia, where there is only one prescription drug coverage scheme 
for the whole country. 
 
Medicare cover does not include prescription medicines outside of hospitals.(8, 
37) Therefore, each province/territory has its own prescription drug plan. 
Residents may use the provincial/territorial plan, or buy private health insurance 
which includes prescription medicine coverage.(8) There are also Federal Public 
Drug Benefit Programs, which provide coverage for the following groups; First 
Nations and Inuit people, people serving in the Royal Canadian Mounted Police, 
people serving in the military, veterans, and inmates in federal prisons.(38) People 
enrolled with the NIHBP are able to have any fees sent directly to the Program, and 
so they do not pay directly for prescription costs.(39) 
 
The provinces and territories have drug plans which contribute to the cost of 
medicines. Each drug plan has a list of medicines covered known as a 
formulary.(40) Private insurance plans in Canada have similar formularies. The 
Canadian Agency for Drugs and Technologies in Health (CADTH) reviews new 
medicines to be added to provincial/territorial formularies for all regions except 
Québec.(41) CADTH reviews both the clinical- and cost-effectiveness of new 
medicines.(41) Most provincial/territorial drug plans include provision for generic 
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substitution of medicines, which lowers pharmaceutical costs. However, 
prescription charges are not regulated across Canada and vary from pharmacy to 
pharmacy.(41) 
 
Drug coverage varies between provinces/territories. How patients pay for their 
prescription medicines also varies. Not all provinces/territories require their 
residents to be part of a drug plan (public or private). This means that some people 
may have no drug coverage and must pay all fees OOP.(41) In this study, the 
provinces and public drug plans included are; British Columbia (PharmaCare),(42) 
Newfoundland and Labrador (Newfoundland and Labrador Prescription Drug 
Program (NLPDP)),(43) and Québec (Public Prescription Drug Insurance 
Plan).(44) Each of these provinces will now be considered in turn. 
 
British Columbia 
In British Columbia, public coverage is provided by PharmaCare.(42) The main 
plan provided by PharmaCare is the “Fair PharmaCare” plan, which is income-
tested.(45) There are other public plans available to specific patient groups in 
British Columbia, such as those patients with cystic fibrosis or patients receiving 
palliative care.(46)  
 
With the “Fair PharmaCare” plan, the net amount a family earns is used to calculate 
a “deductible”. The deductible is an amount that must be paid in full before 
PharmaCare contributes to medicine costs. After the deductible is reached, 
PharmaCare pays a proportion of medicine costs up to an “annual family 
maximum”. Thereafter, PharmaCare pays all prescription medicine costs, so long 
as these medicines are listed in the PharmaCare formulary.(47) 
 
For example, a family on the median income in British Columbia in 2014 would 
have earned $76,770 (CAD).(48) The annual deductible for this income would be 
$2,250 (CAD). After paying the deductible, this family would then pay for 30% of 
their prescription medicine costs, and PharmaCare would pay the remainder.(49) 
Once the family has contributed a total of $3000 (CAD), all prescription medicine 
costs are fully paid for by PharmaCare.(49) The costs patients must pay until they 
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reach the annual family maximum include dispensing fees (set by the pharmacy) 
and the cost of the medicine.(50)  
 
Newfoundland and Labrador 
The province of Newfoundland and Labrador provides public drug plans to people 
over 65 years, people on low incomes, people who have high prescription costs (at 
least 5% of net annual income), and those with specific illnesses (such as cystic 
fibrosis).(51) The potential co-payment varies depending on which plan a patient 
is enrolled in, for example a person over 65 years in the 65Plus Plan would pay a 
maximum of $6 (CAD) per item, whereas a family covered under the Assurance 
Plan earning up to $30,000 (CAD) would need to pay the first $1,500 (CAD) of 
prescription costs before the plan would contribute.(51) Again, both dispensing 
fees and the cost of the drug would be part of the prescription cost,12 and the 
drugs covered are limited to the Newfoundland and Labrador formulary.(51) 
 
Québec 
In Québec it is mandatory to have some form of prescription drug insurance, 
whether it be public or private coverage.(52) The public drug plan is for people 
over 65 years, people not eligible for a private plans, and those in need of financial 
assistance.(52) Private drug plans are often available for employees or 
professional groups.(53) Children are usually included in the same plan as their 
parents.(53) Most people on the public plan must pay an income-test annual 
premium (up to $640 (CAD) in 2015), whether or not they purchase any 
prescription drugs in that year.(54) When a patient does pay for a medicine, they 
must pay a monthly deductible and co-insurance. The co-insurance is calculated on 
the dispensing fee, drug cost and the deductible, with the plan contributing the 
remaining proportion. There is a maximum monthly contribution of $85.75 (2015), 
after which drugs on the plan are free for the rest of the month. After a maximum 
yearly contribution of $1,029 (2015), all drugs on the plan are free of charge for 
the rest of the year.(54) Patients over 65 years for whom 94% or more of their 
annual income is from government benefits receive prescription medicines free of 
charge. Children under 18 years whose parents are insured under the Public 
Prescription Drug Insurance Plan also receive prescription medicine free of 
charge.(54) Eighteen to twenty-five year olds in full-time education and still living 
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with their parents who are insured under the public plan also receive medicines 
free of charge.(54) Again, this applies only to drugs on the Québec “List of 
medicines” or formulary.(55) 
 
England  
Healthcare in England is provided through the National Health Service (NHS) 
England.(56) The NHS England is funded through general taxation.(8) NHS 
England is responsible for all aspects of healthcare, including hospital care, 
emergency services, mental health care and primary care.(57) Treatment is 
generally free of charge for all services, though there are some OOP costs for 
prescription medicines, dental care and medical devices.(56, 58) Around 10% of 
people purchase private healthcare, which allows quicker access to some 
services.(8) 
 
The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United 
Kingdom is the licensing agency for prescription medicines.(59) Prescription 
medicines must be licensed by the MHRA to be funded by the NHS. Therefore, 
when a licensed prescription medicine is prescribed by a doctor or other approved 
prescriber for a patient it will be funded by the NHS.(60) Prescription medicines 
are free in the other countries of the United Kingdom (Scotland, Wales and 
Northern Ireland). In England however, patients must contribute a co-payment of 
£8.20 (2015) per item for a three-month supply.(61) If patients have more than 
three prescriptions per month or if 12 prescriptions per year are likely to be 
needed, patients may then purchase a prescription prepayment certificate (PPC) 
for either a month (£29.10 in 2015) or a year (£104.00 in 2015). The cost of a PPC 
can also be made by monthly instalments, so patients do not need to meet the full 
cost of the PPC as a lump sum.(61) 
 
Many patients in England are exempt from prescription costs.(61) The exemptions 
include; people over 60 years of age, children under 16 years of age, young people 
16-18 years of age in full-time education, people receiving some government 
benefits, pregnant women and new mothers, and people with certain medical 
conditions. The medical conditions qualifying for the exemption include; people 
13 
 




Finland’s health system is largely decentralised.(62) The Finnish government is 
responsible for their health strategy, the Ministry of Social Affairs and Health 
(MSAH) for health policy, while the municipalities (administrative regions) are 
responsible for providing their residents with primary and secondary 
healthcare.(63, 64) The municipalities are jointly responsible for the running of 
hospitals across twenty different health districts.(65) The Finnish health system is 
mostly funded through general taxation and statutory insurance, these funds are 
largely passed on to the municipalities for the provision of healthcare.(66) Patients 
may then be required to pay some OOP costs for services, including doctors’ 
appointments, out-patient appointments and prescription medicines.(66) 
 
Pharmaceutical services are overseen by the MSAH.(67) Kansaneläkelaitos (Kela), 
the Social Insurance Institution of Finland, is responsible for reimbursing patients 
for their medicines, if the medicine is on the list set by the Kela Pharmaceutical 
Pricing Board.(67, 68) A patient must pay for any prescription medicine at a 
pharmacy, but may then apply to Kela for reimbursement. The amount reimbursed 
by Kela depends on the medicine and the patient’s medical condition/s. In 2015 
there were three grades of reimbursement; basic reimbursement, where 35% of 
the cost of the medicine is reimbursed to the patient; special reimbursement, 
where 65% of the cost is reimbursed; and full reimbursement where 100% of the 
medicine cost is reimbursed and the patient is only required to make a €3 co-
payment.(67) For example, a patient prescribed the medicine metformin, who also 
had type 2 diabetes mellitus (T2DM) would be reimbursed 65% of the cost, but a 
patient without T2DM would only be reimbursed 35% of the cost.(68) There is an 
annual maximum on OOP prescription payments of €612.62 (2015).(67) After the 
annual maximum is reached, all medicines are 100% reimbursed by Kela, although 





All residents in Germany must have health insurance.(8, 70) About 85% of people 
have the default statutory health insurance, also known as “sickness funds” 
(German: gesetzliche Krankenversicherung, GKV).(70, 71) People who earn over the 
threshold (€54,900 per year in 2015), civil servants or those who are self-
employed, may opt out of statutory health insurance and purchase private health 
insurance.(72) Statutory health insurance is based on the principle of solidarity 
and that spreading the cost of healthcare will result in the whole population being 
healthier.(70, 71) To achieve this, members of the statutory health insurance must 
contribute 14.6% of their gross income, though this payment is usually split 
between an employee and employer, each contributing 7.3%.(72) All residents of 
Germany are entitled to the same care, no matter how much they pay into 
statutory health insurance.(70, 72) The spouse and children of a person with 
statutory health insurance may be insured at no additional cost, if they have no 
earnings or earn too little to contribute to statutory health insurance.(72) There 
are several providers of statutory health insurance. Individuals may choose which 
statutory plan they belong to, though all statutory insurers have similar plans.(70, 
72) Pensioners must also have statutory health insurance, but half of the 
contribution is paid by pension insurance.(70) 
 
Prescription medicines that have been given market authorisation in Germany are 
usually covered by statutory insurance plans.(2, 72) A 10% co-payment is usually 
required, up to a maximum of €10 per item.(72) Some groups of people are 
exempt from prescription charges, for example, children under the age of 18.(72) 
Some medicines are also free of charge. Germany is the only country in this study 
providing some coverage for over-the-counter medicines, but this is only for 
children under 12 years of age with disabilities.(70-72) Prescription charges are 
capped at 2% of gross income, or 1% of gross income for people with chronic 




Public healthcare in New Zealand is available to all citizens and permanent 
residents. The New Zealand government pays for publicly funded healthcare from 
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general taxation.(8) Public funding for healthcare is managed by the Ministry of 
Health and District Health Boards (DHBs). The Ministry of Health is responsible for 
health strategy and policy, and the purchase of some services on behalf of 
patients.(73) DHBs are responsible for most of the provision of healthcare and the 
management of hospitals in twenty different districts of New Zealand.(73) All 
hospital services are free to New Zealand citizens and permanent residents, and 
primary care is largely subsidised by the government and DHBs.(74)  
 
The Accident Compensation Corporation (ACC), is the only separate government 
entity providing access to healthcare. In New Zealand, ACC pays for accident- and 
injury-related medical costs (including prescription medicines), for any person 
legally in the country.(75) ACC is funded through a combination of levies and 
general taxation.(75) Private spending on healthcare in New Zealand is mostly in 
the form of co-payments for services in primary care. Patients may choose to 
purchase private insurance. Private insurance in New Zealand is often used to fund 
elective surgery.(8) 
 
The Pharmaceutical Management Agency of New Zealand (PHARMAC) is 
responsible for the funding of prescription medicines in New Zealand.(76) It 
decides on behalf of DHBs which medicines and other products will be subsidised 
for use. PHARMAC is legislated “to secure for eligible people in need of 
pharmaceuticals, the best health outcomes that are reasonably achievable from 
pharmaceutical treatment and from within the funding provided”.(77) The list of 
subsidised medicines is called the Pharmaceutical Schedule.(78) There are several 
parts to the Schedule, including a list for prescription medicines in primary care, 
and a list of medicines available for use in hospitals. Hospital medicines are paid 
for by DHBs.(78) In primary care, PHARMAC pays the subsidy for prescription 
medicines to pharmacies, so patients are only required to pay a co-payment of $5 
NZD at the time of dispensing for fully subsidised medicines for a three-month 
supply.(78) If a medicine is not fully subsidised, a larger co-payment will be 
required, usually the amount over which an equivalent generic medicine is 
available. Prescription medicines on the Pharmaceutical Schedule are free for 
children under 13 years.(78) There is a maximum co-payment of $100 NZD (20 
items) per family per year, after which all fully subsidised prescription medicines 
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are free of charge.(78) Prescription medicines that are not on the Pharmaceutical 
Schedule will not be subsidised by PHARMAC and the patient has to meet the full 
cost (including dispensing fees) of these medicines.  
 
Summary of medical conditions to be included in the study 
Four medical conditions are included in the study to investigate patient costs for 
real medical conditions. The conditions included are: asthma, type 2 diabetes 
mellitus, schizophrenia and metastatic renal cell carcinoma.  Further detail of the 
rationale for choosing these medical conditions is in the Methods chapter. 
Asthma 
Asthma is a chronic obstructive airway disease.(79) It is a major non-
communicable disease, with prevalence varying around the world, and increasing 
with increasing urbanisation.(80) Recent estimates suggest that 334 million 
people worldwide suffer from asthma.(81) Asthma causes around 250,000 deaths 
annually worldwide, and mortality is higher in countries with decreased access to 
medicines.(82) Most of the burden of asthma is in young children and the elderly. 
(81) In developed countries, Australia, England and New Zealand have some of the 
highest rates of asthma.(82)  
 
Asthma and its symptoms are caused by a variety of factors, including genetic, 
epigenetic and environmental factors.(83) Patients experience wheezing and 
shortness of breath, due to inflammation and constriction of the smooth muscle 
and bronchi.(84) Uncontrolled asthma can result in serious morbidity and 
hospitalisation when acute attacks occur.(82) Acute attacks can be caused by 
emotional stress, exposure to some medicines and environmental factors (such as 
allergens, cold, smoking and air pollution).(79) The most effective controls for 
asthma currently are medicines.(79, 83) Lifestyle and dietary interventions appear 
to have a limited effect on asthma symptoms.(79, 83) To control acute attacks and 
chronic asthma symptoms, medicines such as selective beta-2-adrenoreceptor 
agonists (salbutamol, salmeterol) and inhaled or oral corticosteroids (fluticasone, 
prednisolone) are usually used.(85) Selective beta-2-adrenoreceptor agonists 
cause bronchodilation, opening the airways, and are used in the relief of acute 
symptoms. Corticosteroids reduce airway inflammation and are used to prevent 
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symptoms and acute attacks.(85) The need for medicines to control symptoms is 
usually higher during an acute attack, when either increased doses or additional 
medicines may be required. This means that the cost to control asthma symptoms 
and attacks can change depending on how well controlled the patient’s asthma is. 
More visits to a general practitioner may also be necessary during an acute attack, 
further increasing potential costs to the patient.(81)  
 
Type 2 diabetes mellitus 
The number of people suffering from type 2 diabetes mellitus (T2DM) is rising 
rapidly around the world. Around 422 million people are thought to have some 
form of diabetes,(86) and of these 90-95% have T2DM.(87) In developed countries 
(including those included in this study), diabetes prevalence ranges from 7.2–
8.5%.(88) People with diabetes have an increased risk of premature death, with 
43% of all diabetes-related deaths occurring in people under the age of 70.(88) 
This is because of the interaction between diabetes and cardiovascular disease, 
with diabetics 2–3 times more likely to have a stroke or heart attack.(86, 88) In 
developed countries, low-income people are more likely to have diabetes, 
contributing to health disparities.  
T2DM is as a chronic metabolic disease, where inadequate production of, or 
response to insulin leads to high blood sugars.(89) It is different to type 1 diabetes 
mellitus (T1DM), where autoimmune destruction of the pancreatic islet beta cells 
results in no endogenous production of insulin.(87) Various factors contribute to 
the decreased production and response to insulin, including age, increased weight, 
lack of physical activity, ethnicity and the chronic use of some medicines.(87) 
T2DM has a long asymptomatic period, where blood sugars may be high.(90) The 
World Health Organisation (WHO) defines diabetes as a fasting plasma glucose 
concentration of greater than or equal to 7 mmol/L, a 2-hour plasma glucose 
concentration of greater than or equal to 11 mmol/L, or a glycated haemoglobin 
(HbA1c) level of 6.5%.(91) Persistently high blood sugars can result in 
complications such as microalbuminuria and peripheral vascular disease, which in 
turn may lead to renal failure, blindness and amputation of limbs.(86, 88, 92) 
Changes in lifestyle such as maintaining a healthy weight and regular exercise 
often can normalise blood sugars, but if this is inadequate drug therapy may be 
required to manage high blood sugars.(92) The first-line oral drug treatment is 
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metformin,(86, 92, 93) a biguanide, which increases peripheral utilisation of 
glucose and decreases the production of glucagon.(94) If high blood glucose 
concentrations continue despite treatment with metformin, a second oral medicine 
may be added, such as a sulfonylurea (glicazide), a dipeptidyl peptidase-4 inhibitor 
(sitagliptin) or pioglitazone.(93) If these medicines are still unsuccessful in 
lowering blood glucose concentrations, subcutaneous insulin may be required.(87, 
92, 93) 
Patients with T2DM have an increased risk of cardiovascular disease and 
commonly present with comorbidities such as hypertension and 
dyslipidaemia.(87) First-line treatment of hypertension in patients with T2DM is 
usually an angiotensin-converting enzyme (ACE) inhibitor, such as cilazapril, 
perindopril or ramipril, or an angiotensin receptor blocker (ARB), such as losartan, 
as these medicines appear to be renal-protective compared to other anti-
hypertensives.(87, 92) In dyslipidaemia, the first-line treatment is a statin, such as 
simvastatin or atorvastatin.(86, 87, 92)  
Schizophrenia 
There are 21 million people worldwide with schizophrenia.(95) It is one of the top 
twenty conditions contributing to the global disease burden.(96) Schizophrenia 
has a higher incidence in men (15 per 100,000) than women (10 per 100,000).(97) 
People with schizophrenia have a decreased life expectancy by 10-20 years and a 
6.5 % lifetime risk of suicide.(97) Decreased life expectancy is due to the effects of 
schizophrenia on physical health as well as mental health, as many people with 
schizophrenia have significant co-morbidities and reduced access to medical 
care.(98) 
 
The aetiology of schizophrenia is not well understood. Multiple genes appear to 
contribute to the risk of developing schizophrenia, and no single underlying cause 
has yet been found. Environmental factors are thought to contribute, such as 
disruptions to neurodevelopment during pregnancy, socioeconomic factors, 
immigration and cannabis use during adolescence.(97, 98) The pathophysiology of 
schizophrenia is also not well understood and there are no biological markers that 
can definitively diagnose the disease.(98) Schizophrenia is diagnosed on the basis 
of symptoms experienced by the patient, the first symptom noticed often being an 
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episode of acute psychosis.(97) Symptoms include the experience of delusions, 
hallucinations, disordered thought, cognitive impairment, depressed mood and 
social withdrawal, a presentation with a combination of these symptoms is used to 
diagnose schizophrenia.(98, 99) Some of these symptoms can also occur with other 
mental illnesses, making diagnosis complicated.(98) Changes in brain chemistry, 
particularly the regulation of dopamine and glutamate, are thought to contribute to 
symptoms, and the medicines currently available for schizophrenia relieve 
symptoms through dopamine blockade.(97) There are no medicines to treat the 
cause of schizophrenia.(98) Second-generation or atypical antipsychotic 
medicines, such as risperidone, olanzapine or quetiapine, are the mainstay of 
treatment. They are usually used during the initial acute phase of illness to control 
symptoms, and are often continued as maintenance treatment long-term. Second-
generation antipsychotics are preferred over first-generation antipsychotics as 
they are better tolerated and have reduced extrapyramidal effects. However, 
second-generation antipsychotic medicines also have serious long-term effects, 
such as weight gain, dyslipidaemia and hyperglycaemia.(98) Antipsychotic 
medicines do not combat all of the symptoms of schizophrenia, tending to alleviate 
only the positive symptoms (such as delusions and hallucinations) and not the 
negative symptoms (changed affect and mood).(97) The antipsychotic medicine 
someone is started on may have to be changed if adverse effects become 
intolerable, or if symptoms are not adequately controlled.(98) Clozapine is 
reserved for patients with treatment-resistant schizophrenia (usually treatment 
failure on two other second-generation antipsychotics), as it can cause 
agranulocytosis and neutropenia, which require long-term monitoring.(97-99) 
 
Metastatic renal cell carcinoma 
Renal cell cancers are the 7th most common cancer in developed countries, with 
337,680 new cases diagnosed worldwide in 2012.(100) Renal cell carcinoma (RCC) 
is a subtype of renal cancer, making up 90% of all renal cancers.(101) Around 17% 
of patients with RCC have metastatic disease (metastatic RCC) at the time of 
diagnosis.(102) RCC is more common in men, older people and in developed 
countries, though the reason for this is unknown.(103) Overall survival rates for 
RCC in developed countries have increased in the last 30 years, with mortality 




RCC is a malignancy of the epithelium of the renal tubules.(101) The mainstay of 
treatment for RCC is surgery to remove the tumour, but this is not always possible 
with metastatic RCC.(103, 105) Drug therapy is therefore required to prevent 
disease progression. Previously, patients were treated with immune modulators 
such as interferon alfa and interleukin 2, but these treatments were limited by 
toxicity and poor response.(105, 106) New drug therapies targeting the vascular 
endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) 
pathways have been developed in the last 10 years(105) and these have become 
the first-line drug treatment for metastatic RCC. Sunitinib is a tyrosine kinase 
inhibitor, which inhibits both BEGF and PDGF receptors. It has been shown to 
improve both progression-free survival and overall survival compared with 




As health and pharmaceutical expenditures rise, some of the costs will be passed 
on to patients. There are a variety of strategies to contain costs and to share costs 
with patients. Some groups of people are less able to meet the challenges of rising 
healthcare and prescription costs. There are few studies which have investigated 
how much patients are expected to pay for medicines outside of a single medical 
condition or age group, and also compared costs to patients between different 
countries. This thesis aims to examine patient costs of prescription medicines in 
Australia, Canada, England, Finland, Germany and New Zealand for model patients 
with asthma, type 2 diabetes mellitus, schizophrenia and metastatic renal cell 
carcinoma, and describe what proportion of patients’ income is spent to treat these 
conditions.  
The aim of this thesis is to examine costs of prescription medicines incurred by 
patients in a variety of high-income Organisation for Economic Co-operation and 
Development (OECD) countries. This thesis reviews the literature related to 
pharmaceutical pricing policy and patient prescription charges. The methods of 
gathering information to compare medicine prices for in the different countries 
are then outlined. Results for what patients may pay in each scenario, and what 
proportion of their income this could be, are then presented. How this research 
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The objective of the literature review was to identify and summarise studies 




A review of the literature was performed to assess the available information on the 
topic of medicine prices in OECD countries. The databases used were Medline, 
Embase and Scopus. The search string “drug therapy” OR “prescription” OR 
“prescription drug” OR “medication” AND “drug cost” OR “price” OR “fee” OR “cost” 
OR “charge” OR “finance “OR” co-payment “OR “out of pocket” OR “payment” OR 
“prescription charge” AND “OECD” OR “organisation for economic co-operation 
AND development” was used and mapped to Medline Medical Subject Headings 
(MeSH) terms where available. The term “pharmaceutical” was not specifically 
searched for, as it was included under the MeSH heading for “drug therapy”.  
The search yielded 72 studies (once duplicates were removed). Results for all 
countries in the OECD were included. Searching for the individual countries to be 
included in this thesis produced no additional results. Studies not relevant to 
medicine costs, dealing with non-OECD countries, not in English or not available in 
full-text were excluded from the review. After these exclusions, 30 papers were 
included in the review. As the search resulted in many heterogeneous descriptive 




Three key themes were identified in the papers reviewed. “Pharmaceutical 
expenditure in different countries” contains papers where pharmaceutical 
expenditures were compared across different countries and explored for 
individual countries. “Pharmaceutical Policies for Funding Medicines” includes 
23 
 
papers discussing the various policies and strategies used by different countries 
and health systems to contain pharmaceutical costs. “Out-of-pocket costs” reviews 
the papers that investigated direct healthcare costs to patients, rather than overall 
costs to health systems. Some papers included elements from more than one 
theme. 
Pharmaceutical expenditure in different countries 
Pharmaceutical expenditure comparisons between countries 
Comparisons of national expenditure are useful for policy makers and health 
funding agencies, but comparing national expenditures can be very difficult.(109) 
This is due to the multiplicity of systems providing healthcare in different 
countries and the databases reporting this information are difficult to 
compare.(109, 110) The diverse ways of expressing drug prices, such as ex-
manufacturer price, public price, and the currency exchange rate, have advantages 
and disadvantages. However, giving prices in United States Dollars (USD) using 
Purchasing Power Parities (PPP), based on OECD data, was the most common 
method used to compare expenditure.(109, 111, 112) 
High-income countries are increasingly concerned about the amount of money 
spent on healthcare and particularly on medicines.(110, 113) This has led to 
comparisons of national expenditure between different high-income countries in 
the OECD.(111, 112, 114) LeLorier et al compared cardiovascular drug 
expenditure for Canada, Australia and New Zealand. They found that Canada spent 
the most on pharmaceuticals, as well as healthcare in general.(112) Both Squires 
and Kanavos included the USA in their studies of pharmaceutical expenditure.(111, 
114) They found that, compared to the other high-income countries, the USA spent 
more on pharmaceuticals, used more pharmaceuticals and also paid more for the 
same pharmaceuticals when compared with other countries. Higher spending by 
the USA did not necessarily result in better health outcomes for patients.(114) 
People with chronic conditions fared worse in the USA compared to other high-
income countries.(114) For the countries in this thesis, Australia, Canada, England 
Finland, Germany and New Zealand, health and pharmaceutical spending 
information is given in Table 1. 
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Pharmaceutical expenditure in individual countries 
Studies on the expenditure of individual countries, were identified for; 
Belgium,(115) Canada,(116, 117) Ireland,(118) Japan(119) and the USA.(120) In 
Belgium, public, private and out-of-pocket (OOP) drug costs all increased over the 
period 1990-1999.(115) Canada is the second highest spender on medicines in the 
OECD after the USA.(116) Canada’s prescription drug costs are not covered by the 
public health system, which leaves patients vulnerable to high costs for 
medicines.(117) In Ireland, despite the increased use of generic medicines and 
other cost-containment strategies, drug costs have increased and this cost has 
been passed on to consumers with an increase in the standard prescription 
price.(118) Overall healthcare costs are increasing in Japan, though drug costs 
were not particularly focused on by Sasaki.(119) In the USA, Reinhardt et al 
identified that overall healthcare costs and pharmaceutical costs are rising at a 
greater rate than other countries due to multiple factors unique to the USA.(120) 
These factors included; disjointed organisation and multiple layers of 
administration that are not present in other countries.(120)  
Pharmaceutical expenditure for specific drugs 
Three studies explored expenditures for specific groups of drugs. Two studies 
focused on the increasing expenditure on antimicrobials.(121, 122) They discussed 
the clinical impacts and appropriateness of use of antimicrobials. (121, 122) These 
were also considered from a prescribing and clinical point of view rather than 
expenditure or direct costs to patients.  Litchenberg (2009) concentrated on new 
and expensive drugs, particularly cardiovascular drugs and concluded that 
expenditure on these drugs should increase to give better health outcomes.(123) 
These studies established that drug costs are rising at both national and 
international levels. While this may be appropriate, few of these studies 
investigated further into whether and how these costs may be passed on to 
patients in each country. 
Pharmaceutical Policies for Funding Medicines 
Pharmaceutical policies vary widely between different OECD countries. Most high-
income countries in the OECD have some form of social insurance system to cover 
healthcare, exceptions being the USA and Mexico.(124) Alongside these systems, 
most high-income countries also have an agency responsible for assessing both the 
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clinical- and cost-effectiveness of new prescription medicines,(125) such as the 
Canadian Agency of Drugs and Technology (CADTH) in Canada,(126) and the 
National Institute for Health and Care Excellence (NICE) in the United 
Kingdom.(125) 
Many countries have employed cost-reduction strategies in their pharmaceutical 
policy to contain rising pharmaceutical expenditure. Cost reduction strategies 
include the use of reference pricing, generic medicines, the use of a formulary, 
insurance plans and patient co-payments. For example, Austria uses a formulary, 
insurance, contribution limits and means testing.(127) Universal healthcare in 
Canada does not cover prescription medicine use outside of hospitals(126) and so 
the provinces each have different approaches to cost containment for their public 
drug plans. These include the use of the above-mentioned strategies.(128)  
Reference pricing is employed by many countries as a cost-saving strategy.(124) 
The use of reference pricing and generic medicines generally decreases 
pharmaceutical expenditure.(129) Australia’s Pharmaceutical Benefits Scheme 
(PBS) and New Zealand’s Pharmaceutical Management Agency (PHARMAC) both 
use reference pricing and brand substitution to reduce costs and improve patient 
access to medicines.(130, 131) However, the outcomes for patients when reference 
pricing is used are less well known. Acosta et al found some evidence to suggest 
that reference pricing may reduce medicine prices for patients, but little is known 
as to whether this leads to improved health outcomes.(132) 
Cost-sharing between funders and patients, often taking the form of a co-payment, 
is another strategy used in many OECD countries. Angus states that cost-sharing is 
justified because it reduces patient demand, increases appropriate use and 
increases efficiency.(128) The amount of cost-sharing, usually in the form of a co-
payment, may be subject to further criteria, such as socio-economic class, age or 
presence of a chronic condition.(133) Other cost-sharing mechanisms include 
contribution limits, co-insurance, and deductibles. These systems are difficult to 
compare in terms of their effect on expenditure and on patients.(134) However, 
increasing the patient’s share of the cost (by increasing the co-payment), may 
prove a barrier to treatment and decrease patient use of medicines.(133, 134) This 




Out-of-pocket (OOP) costs 
A small number of studies focused on OOP costs to patients. Three studies 
investigated patient OOP costs associated with healthcare. OECD countries are 
increasing OOP costs for healthcare in order to contain rising expenditures. 
However, this can lead to inequalities in access, as low income individuals over 65 
years were found to pay the highest OOP costs in relation to income.(135) Corrieri 
et al also found other groups more vulnerable to healthcare costs included those 
with less education and women.(135) Of the OOP healthcare costs, prescription 
medicines made up the biggest proportion of costs. This could result in patients 
not taking their medicines to keep their costs down. Kemp et al looked at a sample 
of OECD countries and related OOP prescription medicine costs to income.(136) 
Using OECD data on per capita expenditure of medicines, they found that the 
average percentage of household income spent on medicines in OECD countries 
varied from 0.15% in Spain, to 1.66% in the USA.(136) New Zealand was not 
included in the study due to lack of data available on private expenditure.(136) 
In Australia, Carpenter et al conducted a survey of household expenditure on 
healthcare in people over 50 years.(137) Those with the highest income had a 
mean spend of $151 AUD on medicines over a 3-month period, while those with 
the lowest income had a mean spend of $542 AUD over 3 months. This further 
demonstrates that people with lower incomes are more vulnerable to OOP costs. 
Strategies to be able to pay for medical care included using savings, borrowing 
money and selling assets.(137) 
One study specifically examined the OOP costs of a chronic disease and compared 
those costs between different countries. The costs associated with rheumatoid 
arthritis in industrialised countries were investigated by Pugner et al 2000.(138) 
They compared direct costs between countries using purchasing power parities, 
and the mean total cost to patients across the countries was $5054 USD. Of this, 
drug costs were a median of 16% of the total cost to treat rheumatoid 
arthritis.(138) As with other chronic diseases, people with rheumatoid arthritis 
represent a patient group vulnerable to rising OOP costs, as 70% of these patients 
were no longer able to work.(138) 
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Limitations of the review 
Grey literature was included for analysis in some of the papers reviewed. The 
process of publishing grey literature may be less rigorous than with scientific 
papers, but some of the information on pharmaceutical policy, is unlikely to be 
found from sources other than grey literature. Grey literature was not included 
directly as part of the literature review, which means useful information on high-
income countries’ pharmaceutical policies and expenditure may have been missed. 
Some of the papers were more than 15 years old and the policies discussed may 
have changed since publication. Papers in languages other than English were not 
included, and so the perspectives and cost-containment strategies of some high-
income countries may not have been considered. Low and middle-income 
countries were not included in the review and they may have offered different 
approaches to pharmaceutical policy and spending. Patient and physician views on 
prescription charges are not well studied. Few of the papers reviewed included the 
impact of pharmaceutical policies or prescription charges on patient health 
outcomes or the ability of patients to access prescription medicines. 
 
Conclusion 
The literature reviewed established that high-income countries are concerned 
about their pharmaceutical expenditure. Data from the OECD is frequently used to 
compare high-income countries and is seen as reliable. Using Purchasing Power 
Parities is considered a better means to compare pricing between countries at a 
given point in time, rather than converting prices into a common currency. While 
many cost-containment strategies have been developed, the impact of these 





The aim of this thesis is to examine patient costs of prescription medicines in a 
variety of high-income Organisation for Economic Co-operation and Development 
(OECD) countries. Model patient scenarios are used, with different medical 
conditions, ages and incomes, to explore the financial burden that patients may 
face for prescription medicines. No studies were found when reviewing the 
literature that compared different countries’ patient co-payments for prescription 
medicines in patients with different medical conditions, ages and incomes. This 
research explores the differences in payment methods and co-payments between 
different countries, but not the direct impacts on real patients or their health. 
 
Country selection 
Six countries were selected to be included in this study. The inclusion criteria for 
countries were that; each country included should be a high-income country 
belonging to the OECD, and countries should have a public health system, which 
subsidises the costs of medicines for at least some groups of patients and attempts 
to protect patients from excessive prescription charges. 
This meant that the United States of America (USA) was not included. The USA 
healthcare system is extremely complicated and there is no universal coverage for 
the general population.(8) While there is some public coverage of prescription 
medicines for certain groups of patients, there are also many different policies and 
formularies that regulate this, making comparison with other countries extremely 
difficult.(8) There are also coverage gaps for prescription medicines, which are not 
present in most other high-income countries.(8) 
To assist with locating data sources, provide local knowledge and to verify that 
information on each country was correct and current, a collaborator from each 
country was approached. The collaborators needed to be able to translate the local 
language if information could not be obtained in English. The collaborators also 
needed excellent knowledge of the pharmaceutical system at a policy level as well 
as knowledge about drug prices or links to other reliable sources of this 
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information. The countries where potential collaborators were found were; 
Australia, Canada, England, Finland and Germany. In Canada, collaborators were 
found in British Columbia, Newfoundland and Labrador, and Québec. The Canadian 
Federal system was also included. This provided a range of different arrangements 
for funding medicines. Only England was included from the United Kingdom, as 
patients in England pay for some prescription medicines. Patients in Northern 
Ireland, Scotland and Wales, receive all medicines free of charge from their 
pharmacy.(139-141) Background information on prescription medicine policies 
and co-payments for each country has been outlined in the introduction. 
The international collaborators for this project were: 
• Professor Elizabeth Roughead, a research professor in the School of 
Pharmacy and Medical Sciences at the University of South Australia. She has 
an expertise in problems with medicines use and pharmaceutical policy 
development(142); 
• Professor Steven Morgan, professor of health policy at the School of 
Population and Public Health, University of British Columbia, Canada. 
Professor Morgan’s field of research includes equitable access to medicines 
and pharmaceutical policy(143); 
• Ms. Jennifer Donnan, Drug Information pharmacist and doctoral candidate 
at the School of Pharmacy, Memorial University of Newfoundland, 
Canada(144); 
• Dr John Hawboldt, associate professor at the School of Pharmacy, Memorial 
University of Newfoundland, Canada. His research experience includes 
pharmacy practice(145); 
• Professor Robyn Tamblyn, Department of Medicine and Department of 
Epidemiology and Biostatistics, McGill University, Montreal, Canada. She 
holds the positions of Medical Scientist at the McGill University Health 
Center Research Institute, and the Scientific Director of the Clinical and 
Health Informatics Research Group at McGill University. Professor Tamblyn 
has expertise in prescription drug use and improving the safety and quality 
of health care(146, 147); 
• Dr Ellen Schafheutle, senior lecturer at the Manchester Pharmacy School, 
University of Manchester, England, who is a pharmacy policy 
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researcher(148). Dr Schafheutle is originally from Germany, and was also 
able to advise on healthcare in Germany; and 
• Ms. Katri Aaltonen, researcher with Kela – the Social Insurance Institution 
in Finland, who has an expertise in cost-related barriers to prescription 
medicine use(149). Katri is also completing her PhD studies in the 
affordability of medicines in Finland and New Zealand. 
Information on the public health systems, mechanisms for the funding of 
medicines and patient co-payment systems was obtained. The primary sources for 
this were the government organisations responsible for healthcare and the funding 
of medicines in each country or province:  
• the Pharmaceutical Benefits Scheme (PBS) in Australia(150);  
• Pharmacare in British Columbia(42);  
• the National Health Service in England(57);  
• Kansaneläkelaitos (Kela), the Social Insurance Institution, in Finland(151);  
• Bundesministerium für Gesundheit (BMG), the Federal Ministry of Health 
Germany,(152) and Spitzenverband, the National Association of Statutory 
Health Insurance Funds,(153) in Germany; 
• the Newfoundland and Labrador Prescription Drug Program (NLPDP) in 
Newfoundland and Labrador(43); 
• the Pharmaceutical Management Agency (PHARMAC) in New Zealand(77); 
and 
• Régie de l'assurance maladie du Québec (RAMQ) in Québec(44). 
The collaborators provided further information when it could not be obtained 
from the above sources. The prices of the medicines and patient co-payments to be 
included in the study were also found from these sources where prices are publicly 
available, or sought from the collaborators. They were then converted into United 
States Dollars using Purchasing Power Parities from the OECD for 2015 to allow 
for price comparisons. 
Additional background information was sought from the OECD, the World Bank, 
the World Health Organisation (WHO) and other governmental and non-




Medical conditions to be investigated 
The medical conditions investigated were discussed with the collaborators. Each 
medical condition needed to be treatable with medicines. The medical conditions 
should be treated with similar, if not the same medicine or group of medicines, in 
each country to allow for comparison of what patients might pay to treat their 
conditions. The medical conditions should be chronic conditions, with on-going 
need for treatment with medicines to prevent complications or symptoms. Ideally 
this would include a medical condition that might have exacerbations (as therefore 
the cost of medicines might vary rather than being constant over a given time 
period), a medical condition affecting children, a mental health condition (as these 
patients can be particularly vulnerable to the cost of medicines), a medical 
condition that was relatively rare, and a medical condition for which drug 
treatment is currently very expensive.  
Information on which medicines are used for the medical conditions in each 
country were then gathered from national guidelines or other local sources such 
as, the National Institute for Health and Care Excellence (NICE). These were then 
checked with the local collaborators for each country. The conditions chosen are 
listed here with a discussion of the rationale for their inclusion. Clinical 
information about each condition was described in the introduction. 
Asthma 
Asthma and chronic obstructive pulmonary disease (COPD) were considered as 
patients with either of these medical conditions are prone to acute exacerbations 
and the requirement for treatment may vary over time.(85) Asthma was chosen as 
a medical condition for this study for two reasons. The first is that it is a condition 
for which the medicine requirements can fluctuate and the same medicines may 
not be required in the same amounts year-round. These two factors are different 
from the treatment regimens for other chronic conditions. Secondly, asthma is a 
condition that affects children as well as adults, unlike COPD. This allows the study 
to assess the medicine costs that a family may have to bear with a sick child. 
Asthma usually begins in childhood, can persist into adulthood, but can also begin 
in adulthood.(79) Childhood asthma can interfere with schooling and social 
interactions. Adult asthma can result in missed work and loss of productivity.(83) 
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Asthma has a significant impact on sufferers both socially and financially. In New 
Zealand, hospital admissions for asthma occur most often in Māori, Pacific Island 
peoples and those living in deprived areas.(154) The cost of medicines to control 
asthma may contribute to the number of hospital admissions and morbidity, 
particularly for low-income people. 
Type 2 diabetes mellitus  
Type 2 diabetes mellitus (T2DM) was chosen as a condition for this study because 
it can cause serious morbidity, such as blindness and renal failure, and mortality, 
these outcomes may be prevented by adherence to lifestyle changes and the use of 
medicines.(87) There is an increasing burden of T2DM in both the developed and 
developing worlds as obesity increases.(86) T2DM presents significant economic 
losses for both countries and individuals. The estimated loss of income due to 
diabetes from 2011–2030 is $900 million USD in developed countries, and $1.7 
trillion USD for the world.(88) For an individual, complications due to diabetes can 
result in lost work, disability and catastrophic medical expenditure.(87) As 
complications can be prevented using medicines, removing barriers to treatment is 
important for these patients. 
Schizophrenia  
In the context of this study, schizophrenia was chosen as a condition because 
patients with mental illness are a vulnerable group.(95) Schizophrenia is 
associated with social stigma and human rights abuses.(95) Half of patients 
diagnosed have long-term mental health problems, coupled with an increased risk 
of other conditions such as metabolic syndrome, smoking and obstructive sleep 
apnoea.(98) This impacts on participation in work and education,(95) resulting in 
80-90% of people with schizophrenia needing some form of income support.(97, 
98) This means that co-payments for medicines may be a barrier for patients with 
schizophrenia accessing treatment and lack of access to treatment can be 
detrimental to patients.(96) 
Metastatic renal cell carcinoma 
Metastatic renal cell carcinoma (RCC) was chosen as a condition for this study as it 
is relatively rare.(97) With cancer being the most common cause of death in 
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countries such as New Zealand,(155) it also reflects the increasing cancer burden 
that developed countries are facing. There are also considerable financial 
implications in the treatment of cancers.(105) For example, sunitinib, one of the 
main drug therapies used in the treatment of metastatic RCC is currently still 
under patent and a generic is unlikely to be available for several years. The 
treatment of metastatic RCC therefore is also representative of the cost of new 
medicines, and how they can be extremely expensive when first released to the 
market.(156) This is particularly important in cancer treatment, as some health 
insurers do not cover the cost of oral cancer treatment, increasing the financial 
burden on patients and public health systems.(156) 
 
Comparing prices 
There is no worldwide common currency. Therefore, a way to compare prices was 
required. One option is to pick one currency and use exchange rates to convert 
other currencies. While this results in a common currency, it does not reflect how 
much one currency may be worth in another market, or what the “buying power” 
of a currency is.(157) Exchange rates can also change rapidly.(157) Purchasing 
power parities (PPPs) take into account economic growth and size of countries. 
They are “price relatives that show the ratio of the prices in national currencies of 
the same good or service in different countries”.(158) PPPs are calculated by 
taking a sample of goods and services in different countries. (158) This means that 
PPPs fluctuate less and are a fairer way to compare prices of items, such as 
prescription prices, between different countries. This has been amusingly 
demonstrated by The Economist’s “Big Mac Index”.(159) The PPPs at the time of 




Table 2. Purchasing Power Parities for actual individual consumption, 2015(158) 
Country Unit  National currency per US dollar 
Australia Australian Dollar (AUD) 1.510725  
Canada Canadian Dollar (CAD) 1.309193  
Finland Euro (EUR) 0.931363  
Germany Euro (EUR) 0.778824  
New Zealand New Zealand Dollar (NZD) 1.454794  
United Kingdom Pound Sterling (GBP) 0.755031  
United States US Dollar (USD) 1.000000  
Initially only the cost to the patient or what a patient would pay at a pharmacy was 
considered. However, in four of the countries; Australia, Canada, Finland and 
Germany, the price the patient pays for the medicine changes depending on the list 
price (the price the drug buying agency has provided). For this reason, the list 
price is also included in the data gathered. The period of collection for this data 
was 2015-2016. Prices for the medicines to be included were then sought from 
funding agencies, insurers and other sources such as the British National 
Formulary (BNF) in each country and province.  
 
Model patients 
To best demonstrate the burden of prescription costs on patients, it was decided 
that a range of model patients would be used. The model patients reflect different 
age groups and income types. In particular, some of the model patients needed to 
be from groups vulnerable to prescription costs. In discussion with the 
collaborators, a range of ages, income types and family situation were agreed upon, 





Table 3. Model patient scenarios 
Age (years) Income type 
70 National pension 
70 National pension + supplementary income (“average wage” for a 70-
year-old) 
35 Minimum wage, working 30 hours per week* 
35 Median individual wage  
35 Unemployed – receives a benefit/welfare payment 
35 Invalid – receives an invalid or sickness benefit (living in the 
community) 
20 Student –  full-time student  
20 Working – median wage for employed people this age  
5 In a family of 4 – earning minimum wage, 40 hours per week 
5 In a family of 4 – earning median income 
5 In a single parent family, on unemployment benefit 
*In some countries, including Canada, Finland, and New Zealand 30 hours work 
per week is considered to be full-time work by government agencies.(160, 161)  
These patients have a variety of different income levels. Income level is also 
affected by age and family situation. The proportion of income spent on 
prescription medicines for the different medical conditions is likely to vary 
between each patient scenario and country, revealing how the financial burden 
may be quite different given the patient, medical condition or country the patient 
lives in. As they are not “real” patients, this will not result in a true financial impact 
or discussion of health outcomes. Patient incomes are reported in the results 
chapter. 
The main sources for patient incomes were national statistics offices and agencies 
responsible for government benefits and income support. Median incomes for 
individuals were found in census and other statistical data from the Australian 
Bureau of Statistics, Statistics Canada, the Office for National Statistics UK, Her 
Majesty’s Revenue and Customs UK, Statistics Finland and Statistics New 
Zealand.(162-167) The years of census data collection were 2010-2015. Incomes 
for people receiving government benefits were sourced from local government 
sources for 2015-2016.(151, 168-173) When incomes were unable to be obtained 
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from local government agencies, OECD data was used.(174) This information was 





Model patient incomes 
Table 4 gives the incomes for each model patient in 2015, in both the local 
currency and in United States Dollars (USD), calculated using purchasing power 
parities (PPPs) for 2015.(158) The PPPs used were the “actual individual 
consumption” and are shown in Table 2. Once converted to USD using PPPs, some 
of the incomes are generally comparable, such as the 70-year-old on a national 
pension, or those on minimum wage. However, for some of the other model 
patients, there is far more variation in income, such as the 35-year-old on an 
invalid’s benefit.  
The incomes identified for German patients receiving benefits are likely to be an 
under-estimate. The reason for this is most people in Germany will have access to 
other funds through social insurance.(72) There are limited public finds available 
in many countries for students, and in the UK the income specified is for a standard 
student loan amount for living costs, rather than true income.(175) 
 
Model patient prescriptions 
The combinations of medicines used to treat the conditions in each country were 
based on regional/national guidelines where available. This information was also 
checked by the collaborators. Where regional guidelines were not available, the 
collaborators provided information on what medicines would be used for each 
condition. The doses given for all medicines included are within the recommended 
dose ranges for the specified conditions. 
The medicines used in the treatment and control of asthma are the same in all 
countries.(85, 176-180) The short-acting beta-agonist (SABA) salbutamol is used 
as needed to relieve acute asthma symptoms. An inhaled corticosteroid and long-
acting beta-agonist (LABA) are used in all countries to prevent asthma symptoms. 
A combination inhaler of fluticasone (corticosteroid) and salmeterol (LABA) is 
available in all countries. Fluticasone and salmeterol are also available as separate 




Table 4. Annual incomes for model patients 
Age and income 
type 

























































Not available Not available $22,400.00 
($15,397.37) 







































Not available $33,600.00 
($23,096.05) 






















35 – invalid, 
receives an invalid 
or sickness benefit 












































Table 4. cont’d 
Age and income 
type 




















20 – median 














Not available Not available $9,800.00 
($6,736.35) 












































5 – single parent 
family of 2, on 
invalid or sickness 


















Not available $29,434.60 
($20,232.87) 
a In Germany, people pay into insurance schemes for loss of income and pensions. The amount paid out depends on what the individual has paid into the scheme and the 
length of employment and unemployment. The amount given here is the minimum basic assistance provided by the German government, but most people would have 
access to further funds.  
b Median income for aboriginal individuals in Canada  
c In Canada, unemployment and sickness benefits depend on previous earnings/hours worked and the regional unemployment rate. The maximum income that could be 
insured for in 2015 was $49,500. The amount given is for the maximum.  
d Some have non-taxable components.  





For type 2 diabetes mellitus (T2DM), there was some variation in the medicines 
used in each country. All countries use metformin as a first-line anti-diabetic 
medicine.(92, 93, 181-183) The add-on treatment is usually a sulfonylurea 
(gliclazide), but in Europe, a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin) 
is used.(92, 93, 181-183) Other add-on anti-diabetic medicines are available in all 
countries. An angiotensin-converting enzyme (ACE) inhibitor is used first-line for 
the treatment of hypertension in T2DM patients in all countries, though the choice 
of ACE inhibitor varies. Cilazapril is used in New Zealand, perindopril in Australia, 
England and Finland, and ramipril in Canada and Germany, though there are a 
variety of ACE inhibitors available in each country.(92, 93, 181-183) Atorvastatin, 
a statin used to control hyperlipidaemia in T2DM, is used in all countries.(92, 93, 
181-183) 
There is a range of anti-psychotic medicines available in all countries for the 
treatment of schizophrenia.(98, 184-186) Risperidone is often used in all countries 
except Finland as a first-line treatment. In Finland, olanzapine is more likely to be 
used.(187) All countries use clozapine for treatment-resistant schizophrenia 
(second-line therapy). 
Several oral medicines are available for the treatment of metastatic renal cell 
cancer. Sunitinib is one of the preferred medicines currently, and is used in all 
countries in the study.(105) 
Drug prices 
List prices 
Where available, list prices for medicines in each country/province were obtained 
from the public funder or public plan.(34, 78, 188-191) This was with the 
exception of England, where prices were found in the British National 
Formulary,(192) and Germany, where prices were found through the National 
Association of Statutory Health Insurance Funds.(193) These are presented in local 
currency and unit of funding (usually pack size or dose unit) in Table 5. Prices 
given are for 2015. Table 6 gives the prices in USD using PPPs, per unit dose, i.e. 
per tablet, capsule or inhalation. This allows for comparison of list prices between 
the different countries/provinces. New Zealand consistently has the lowest prices 
41 
 
for all medicines except sunitinib, which is the most expensive medicine included 
in the study, and New Zealand pays the highest price for it. Prices for Canada’s 
Non-Insured Health Benefits Program (NIHBP) are not included as these prices are 
confidential,(194) as was the price of sunitinib in British Columbia.(195) Prices 
were unable to be sourced for Germany, as there is no public plan for medicines. 
Patient prices 
The prescription charges for medicines are usually sourced from the funding 
agency responsible for the list price or the supply of medicines.(34, 78, 188-192, 
196) However, for additional charges, such as pharmacy mark-ups and dispensing 
fees, the collaborators involved in this study provided the information. Additional 
information, whereby which patients are eligible for reduced prescription charges, 
were found in the information from the agencies responsible for funding 
medicines. Further information was found from other government organisations, 
such as the organisation responsible for benefit payments.  
Exact prices could not be obtained for all medicines in Germany, as there is no 
public drug plan. However, prescription charges in Germany are set at €5-10.(196) 
For the purposes of this study, all prescription charges for Germany were 
estimated at €10 ($12.84 USD using 2015 PPPs) where applicable. The exceptions 
apply to the child aged 5 years, who would be exempt from prescription 
charges,(197) and some of the medicines are available free of charge; salbutamol, 




Table 5. Local list prices for selected medicines (34, 78, 188-193) 
___                  Countries  













































Asthma           
Salbutamol 100 
microgram metered 

































































micrograms + salmeterol 
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___                  Countries  













































Type 2 diabetes with 
hypertension and 
hyperlipidaemia 
         


















































 Not used 
Cilazapril 2.5 mg tablets  Not used Price not 
available 
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100 tablets 
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Schizophrenia           
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Table 6. Medicine prices per dose unit in USD (2015) using PPPs (34, 78, 158, 188-193) 
                       Countries 










































list price Aug 
2015 
 
Asthma           
Salbutamol 100 microgram 
metered dose inhaler (200 
actuations)  
$0.045 Price not 
available 
$0.025 $0.025 $0.052 $0.010 $0.015 $0.091 $0.013 
Fluticasone 250 microgram 
metered dose inhaler (120 
actuations) 
$0.272 Price not 
available 
$0.567 $0.570 $0.484 $0.399 $0.274 Price not 
available 
$0.156 
Salmeterol 50 microgram 
accuhaler (60 actuations) 
$0.416 Price not 
available 
$0.685 $0.775 Not 
available 





micrograms + salmeterol 
25 micrograms (120 
actuations) 
$0.301 Price not 
available 





Table 6. cont’d 
                       Countries 










































list price Aug 
2015 
 
Type 2 diabetes with 
hypertension and 
hyperlipidaemia 
         
Metformin 500 mg tablets 
 
$0.115 Price not 
available 
$0.037 $0.037 $0.034 $0.016 $0.081  Price not 
available 
$0.008 
Gliclazide 80 mg tablets $0.108 Price not 
available 
$0.077 $0.078 $0.071 $0.036  Not used Price not 
available 
$0.016 
Sitagliptin 100 mg tablets $1.373 Price not 
available 
 Not used  Not used  Not used $1.573 $1.340 Price not 
available 
 Not used 
Cilazapril 2.5 mg tablets  Not used Price not 
available 
 Not used  Not used  Not used  Not used  Not used Price not 
available 
$0.033 
Perindopril 4 mg tablets $0.333 Price not 
available 
 Not used  Not used  Not used $0.069 $0.246 Price not 
available 
 Not used 
Ramipril 10 mg tablets $0.341 Price not 
available 
$0.154 $0.155 $0.142 $0.062  Not used $0.182  Not used 
Atorvastatin 20 mg tablets $0.362 Price not 
available 
$0.324 $0.327 $0.300 $0.038 $0.725 $0.204 $0.019 
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Table 6. cont’d 
                       Countries 










































list price Aug 
2015 
 
Schizophrenia           
Risperidone 4 mg tablets $0.719 Price not 
available 
$1.635 $1.043 $0.883  $2.575 Not used $0.423 $0.040 
Clozapine 100 mg tablets $1.824 Price not 
available 
$2.182 $2.191 $2.020 $0.534  $0.540 $1.223 $0.202 
Olanzapine 10 mg tablets $1.104 Price not 
available 
 Not used  Not used  Not used $4.134 $2.264 $1.017 $0.063 
Metastatic renal cell 
carcinoma 
          











In Australia (for patients with concession cards), England, Germany (as outlined 
above) and New Zealand, all prescriptions have a fixed co-payment prescription 
charge. In Canada, Finland and for all other patients in Australia, prescription 
charges are based on the list price of the medicine. In Australia, this is the whole 
cost of the medicine up to a maximum prescription charge of $37.70 AUD. In 
British Columbia and Newfoundland and Labrador, the prescription charge 
comprises of: the whole cost of the drug, mark-up (if applicable) and the 
dispensing fee. The average dispensing fee for British Columbia is $11 CAD and for 
Newfoundland and Labrador $14 CAD. In Québec, prescription charges are 34% of 
the dispensing fee ($11 CAD average) and cost of the drug, with a deductible of $18 
added on to this. A maximum of $85.75 CAD per month may be charged in Québec. 
In Finland, the prescription charge depends on the level of reimbursement 
assigned to the medicine. This may be basic reimbursement (35% of the cost of the 
medicine); special reimbursement, (65% of the cost of the medicine); and full 
reimbursement where the patient is only required to make a €3 co-payment. 
All patients under the NIHBP in Canada receive prescriptions free of charge. In 
Québec, patients over 65 years receiving 94-100% of the pension, and children 
under 18 years are exempt from prescription charges. Patients receiving benefits 
in British Columbia and Newfoundland and Labrador receive prescription 
medicines free of charge. Patients exempt from prescription charges in England 
are; patients over 60 years of age, patients under 16 years of age, patients with 
diabetes or cancer, patients on benefits and patients on low incomes. In New 
Zealand, patients under 13 years of age are exempt from prescription charges. 
For tables 7-41 the prescription charges are usually for one month’s supply of a 
medicine. The prescription charges are calculated for the first prescription of the 
year.  
Tables 7-17 give the prescription charges and proportion of income spent on 
prescription charges for patients with asthma. Those patients on the lowest 
income, not eligible for additional funding, had the largest proportion of income 
spent on medicines. The 20-year-old student in Québec would spend the most on 
prescription charges. Many of the model patients aged 5 years were entitled to free 
prescriptions. Where children aged 5 years were subject to prescription charges, 
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British Columbia and Newfoundland and Labrador had the highest charges, 
ranging between 0.13-0.19% of total family income. 
Tables 18-25 give the prescription charges for patients with T2DM, hypertension 
and hyperlipidaemia. Twenty-year-old model patients were again the most 
affected by prescription charges. Where the prescription for these patients was not 
free of charge, New Zealand has the lowest prescription charge with 0.06% of 
income for a 35-year-old patient on median individual income. 
Tables 26-33 show the prescription charges for patients with schizophrenia. The 
second-line treatment, clozapine, is quite expensive. When the prescription is not 
free or subject to a fixed co-payment, many more patients spent a high proportion 
of income on this medicine. 
Tables 34-41 give the prescription charges for sunitinib in the treatment of 
metastatic renal cell carcinoma (RCC). Many of the model patients would receive 
this treatment free of charge. However, patients not receiving sunitinib free of 
charge or without some kind of prescription charge limit would spend a very high 
proportion of their income on this medicine, particularly in Newfoundland and 
Labrador. 
The average proportion of income spent by model patients in each country and 
province is given in Table 42. This shows the mean and median proportion of 
income spent by all of the model patients for each country and province.  
 
Summary of the main results 
The results for prescription charges range from 0% to over 50% of total annual 
income, depending on the medicine cost, level of income and funding system. 
People on the lowest incomes, such as the 20-year-old patients and those earning a 
minimum wage are most at risk of paying high prescription charges as a 
proportion of their income. Of the medical conditions included in this study, 
metastatic RCC is the most expensive medical condition to treat, followed by 
schizophrenia. The provincial Canadian plans, where patients pay a mixture of 
variable co-payments and deductibles to obtain medicines, also put patients at risk 
of higher prescription charges. 
50 
 
Table 7. Patient aged 70 years, on national pension with asthma. 1-month supply, values given in USD PPP for 2015. Doses: salbutamol 100 
micrograms as required (1 inhaler) + fluticasone 250 micrograms/salmeterol 50 micrograms twice daily (1 inhaler) 




or Province  
Salbutamol 100 microgram 
inhaler (200 actuations)  
Fluticasone 125 micrograms + 
salmeterol 25 micrograms (120 
actuations) 




Proportion of income 
spent on medicines 
Australia 
 
$4.04 $4.04 $8.08 $15,094.74 0.05% 
Canada – NIHBP $0.00 $0.00 $0.00 $13,222.99 0.00% 
Canada - British 
Columbia 
$13.35 $88.78 $30.64 (Patient 
pays 30%) 
$13,222.99 0.23% 
Canada - Newfoundland 
and Labrador 
$4.58 $4.58 $9.16 $13,222.99 0.07% 
Canada - Québec $0.00 $0.00 $0.00 $13,222.99 0.00% 
England 
 
$0.00 $0.00 $0.00 $21,849.43 0.00% 
Finland 
 
$1.03 $12.97 $14 $16,118.31 0.09% 
Germany* 
 
$0.00 $12.84 $12.82 $5315.71 0.24% 
New Zealand 
 
$3.44 $3.44 $6.88 $15,849.91 0.04% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted to 




Table 8. Patient aged 70 years, with median income, with asthma. 1-month supply, values given in USD PPP for 2015. Doses: salbutamol 100 
micrograms as required (1 inhaler) + fluticasone 250 micrograms/salmeterol 50 micrograms twice daily (1 inhaler) 




or Province  
Salbutamol 100 microgram 
inhaler (200 actuations)  
Fluticasone 125 micrograms + 
salmeterol 25 micrograms (120 
actuations) 




Proportion of income 
spent on medicines 
Australia 
 
$4.04 $4.04 $8.08 $12,047.20 0.07% 
Canada – NIHBP $0.00 $0.00 $0.00 $21,284.87 0.00% 
Canada - British 
Columbia 
$13.35 $88.78 $102.13 $20,700 0.49% 
Canada - Newfoundland 
and Labrador 
$4.58 $4.58 $9.16 $16,116.80 0.06% 
Canada – Québec 
 






$0.00 $0.00 $0.00 $38,251.41 0.00% 
Finland 
 
$1.03 $12.97 $14 Not available Unknown 
Germany* 
 
$0.00 $12.84 $12.84 Not available Unknown 
New Zealand 
 
$3.44 $3.44 $6.88 $15,397.37 0.04% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted to 




Table 9. Patient aged 35 years, working 30 hours earning minimum wage, with asthma. 1-month supply, values given in USD PPP for 2015. Doses: 
salbutamol 100 micrograms as required (1 inhaler) + fluticasone 250 micrograms/salmeterol 50 micrograms twice daily (1 inhaler) 




or Province  
Salbutamol 100 microgram 
inhaler (200 actuations)  
Fluticasone 125 micrograms + 
salmeterol 25 micrograms (120 
actuations) 




Proportion of income 
spent on medicines 
Australia 
 
$20.59 $24.95 $45.54 $17,853.94 0.26% 
Canada – NIHBP $0.00 $0.00 $0.00 $12,451.95 0.00% 
Canada - British 
Columbia 
$13.35 $88.78 $30.64 (Patient 
contributes 30%) 
$12,451.95 0.25% 
Canada - Newfoundland 
and Labrador 
$15.69 $90.24 $21.19 (Patient 
contributes 20%) 
$12,213.63 0.17% 
Canada – Québec 
 





$0.00 $0.00 $0.00 $13,843.14 0.00% 
Finland 
 










$3.44 $3.44 $6.88 $15,816.67 0.04% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted to 




Table 10. Patient aged 35 years, median individual income, with asthma. 1-month supply, values given in USD PPP for 2015. Doses: salbutamol 100 
micrograms as required (1 inhaler) + fluticasone 250 micrograms/salmeterol 50 micrograms twice daily (1 inhaler) 




or Province  
Salbutamol 100 microgram 
inhaler (200 actuations)  
Fluticasone 125 micrograms + 
salmeterol 25 micrograms (120 
actuations) 




Proportion of income 
spent on medicines 
Australia 
 
$20.59 $24.95 $45.54 $29,257.48 0.16% 
Canada – NIHBP $0.00 $0.00 $0.00 $20,795.25 0.00% 
Canada - British 
Columbia 
$13.35 $88.78 $102.13 $36,663.81 0.28% 
Canada - Newfoundland 
and Labrador 
$15.69 $90.24 $105.93 $35,823.60 0.30% 
Canada – Québec 
 






$10.86 $10.86 $21.72 $35,495.23 0.06% 
Finland 
 
$1.03 $12.97 $14 $38,176.31 0.04% 
Germany* 
 
$0.00 $12.84 $12.84 Not available Unknown 
New Zealand 
 
$3.44 $3.44 $6.88 $23,096.05 0.03% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted to 




Table 11. Patient aged 35 years, unemployed, receives a benefit/welfare payment, with asthma. 1-month supply, values given in USD PPP for 2015. 
Doses: salbutamol 100 micrograms as required (1 inhaler) + fluticasone 250 micrograms/salmeterol 50 micrograms twice daily (1 inhaler) 




or Province  
Salbutamol 100 microgram 
inhaler (200 actuations)  
Fluticasone 125 micrograms + 
salmeterol 25 micrograms (120 
actuations) 




Proportion of income 
spent on medicines 
Australia 
 
$4.04 $4.04 $8.08 $9,099.07 0.09% 
Canada – NIHBP $0.00 $0.00 $0.00 $20,795.25 0.00% 
Canada - British Columbia $0.00 $0.00 $0.00 $5,591.23 0.00% 
Canada - Newfoundland 
and Labrador 
$0.00 $0.00 $0.00 $4,894.62 0.00% 
Canada – Québec 
 






$0.00 $0.00 $0.00 $10,069 0.00% 
Finland 
 
$1.03 $12.97 $14 $9,122.97 0.15% 
Germany* 
 
$0 $12.84 $12.84 $5,315.71 0.24% 
New Zealand 
 
$3.44 $3.44 $6.88 $10,751.05 0.06% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted to 




Table 12. Patient aged 35 years, receives an invalid or sickness benefit (living in the community), with asthma. 1-month supply, values given in 
USD PPP for 2015. Doses: salbutamol 100 micrograms as required (1 inhaler) + fluticasone 250 micrograms/salmeterol 50 micrograms twice 
daily (1 inhaler) 




or Province  
Salbutamol 100 microgram 
inhaler (200 actuations)  
Fluticasone 125 micrograms + 
salmeterol 25 micrograms (120 
actuations) 




Proportion of income 
spent on medicines 
Australia 
 
$4.04 $4.04 $8.08 $15,094.74 0.05% 
Canada – NIHBP $0.00 $0.00 $0.00 $20,795.25 0.00% 
Canada - British 
Columbia 
$0.00 $0.00 $0.00 $9,013.98 0.00% 
Canada - Newfoundland 
and Labrador 
$0.00 $0.00 $0.00 $4,894.62 0.00% 
Canada – Québec 
 






$0.00 $0.00 $0.00 $14,974.42 0.00% 
Finland 
 
$1.03 $12.97 $14 $16,118.31 0.09% 
Germany* 
 
$0.00 $12.84 $12.84 $5,315.71 0.24% 
New Zealand 
 
$3.44 $3.44 $6.88 $15,126.46 0.05% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted to 
$12.84 USD using 2015 PPPs), where a co-payment applies.  
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Table 13. Patient aged 20 years, student receiving government support, with asthma. 1-month supply, values given in USD PPP for 2015. Doses: 
salbutamol 100 micrograms as required (1 inhaler) + fluticasone 250 micrograms/salmeterol 50 micrograms twice daily (1 inhaler) 




or Province  
Salbutamol 100 microgram 
inhaler (200 actuations)  
Fluticasone 125 micrograms + 
salmeterol 25 micrograms (120 
actuations) 




Proportion of income 
spent on medicines 
Australia 
 
$4.04 $4.04 $8.08 $7,529.50 0.11% 
Canada – NIHBP $0.00 $0.00 $0.00 $2,291.49 0.00% 
Canada - British 
Columbia 
$13.35 $88.78 $30.64 (Patient 
contributes 30%) 
$2,291.49 1.34% 
Canada - Newfoundland 
and Labrador 
$15.69 $90.24 $21.19 (Patient 
contributes 20%) 
$2,291.49 0.92% 
Canada – Québec 
 





$0.00 $0.00 $0.00 $14,174 0.00% 
Finland 
 
$1.03 $12.97 $14 $6,936.41 0.20% 
Germany* 
 
$0.00 $12.84 $12.84 Not available Unknown 
New Zealand 
 
$3.44 $3.44 $6.88 $6,992.94 0.10% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted to 




Table 14. Patient aged 20 years, median income, with asthma. 1-month supply, values given in USD PPP for 2015. Doses: salbutamol 100 
micrograms as required (1 inhaler) + fluticasone 250 micrograms/salmeterol 50 micrograms twice daily (1 inhaler) 




or Province  
Salbutamol 100 microgram 
inhaler (200 actuations)  
Fluticasone 125 micrograms + 
salmeterol 25 micrograms (120 
actuations) 




Proportion of income 
spent on medicines 
Australia 
 
$4.04 $4.04 $8.08 $12,047.20 0.07% 
Canada – NIHBP $0.00 $0.00 $0.00 $7,791.06 0.00% 
Canada - British 
Columbia 
$13.35 $88.78 $30.64 (Patient 
contributes 30%) 
$6,798.08 0.45% 
Canada - Newfoundland 
and Labrador 
$15.69 $90.24 $21.19 (Patient 
contributes 20%) 
$9,089.56 0.23% 
Canada – Québec 
 





$0.00 $0.00 $0.00 $37,354.76 0.00% 
Finland 
 
$1.03 $12.97 $14 Not available Unknown 
Germany* 
 
$0.00 $12.84 $12.84 Not available Unknown 
New Zealand 
 
$3.44 $3.44 $6.88 $6,736.35 0.10% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted to 




Table 15. Patient aged 5, with asthma, in a family of four, earning minimum wage, 40 hours per week. 1-month supply, values given in USD PPP for 
2015. Doses: salbutamol 100 micrograms as required (1 inhaler) + fluticasone 250 micrograms/salmeterol 50 micrograms twice daily (1 inhaler) 




or Province  
Salbutamol 100 microgram 
inhaler (200 actuations)  
Fluticasone 125 micrograms + 
salmeterol 25 micrograms (120 
actuations) 




Proportion of income 
spent on medicines 
Australia 
 
$4.04 $4.04 $8.08 $23,805.26 0.03% 
Canada – NIHBP $0.00 $0.00 $0.00 $16,602.60 0.00% 
Canada - British 
Columbia 
$13.35 $88.78 $30.64 (Patient 
contributes 30%) 
$16,602.60 0.19% 
Canada - Newfoundland 
and Labrador 
$15.69 $90.24 $21.19 (Patient 
contributes 20%) 
$16,284.84 0.13% 
Canada – Québec 
 
$0.00 $0.00 $0.00 $16,761.47 0.00% 
England 
 
$0.00 $0.00 $0.00 $18,457.52 0% 
Finland 
 





$0.00 $0.00 $0.00 $22,700.89 0.00% 
New Zealand 
 




Table 16. Patient aged 5, with asthma in a family of four, median family income. 1-month supply, values given in USD PPP for 2015. Doses: 
salbutamol 100 micrograms as required (1 inhaler) + fluticasone 250 micrograms/salmeterol 50 micrograms twice daily (1 inhaler) 




or Province  
Salbutamol 100 microgram 
inhaler (200 actuations)  
Fluticasone 125 micrograms + 
salmeterol 25 micrograms (120 
actuations) 




Proportion of income 
spent on medicines 
Australia 
 
$20.59 $24.95 $45.54 $34,085.92 0.13% 
Canada – NIHBP $0.00 $0.00 $0.00 $21,284.87 0.00% 
Canada - British 
Columbia 
$13.35 $88.78 $102.13 $58,639.18 0.17% 
Canada - Newfoundland 
and Labrador 
$15.69 $90.24 $105.93 $58,845.41 0.18% 
Canada – Québec 
 
$0 $0 $0 $56,424.07 0% 
England 
 
$0 $0 $0 $54,338.17 0% 
Finland 
 
$1.03 $12.97 $14 $31,106 0.05% 
Germany 
 
$0.00 $0.00 $0.00 $36,176 0.00% 
New Zealand 
 




Table 17. Patient aged 5 years, with asthma, with a single parent receiving an invalid or sickness benefit (living in the community). 1-month 
supply, values given in USD PPP for 2015. Doses: salbutamol 100 micrograms as required (1 inhaler) + fluticasone 250 micrograms/salmeterol 50 
micrograms twice daily (1 inhaler) 




or Province  
Salbutamol 100 microgram 
inhaler (200 actuations)  
Fluticasone 125 micrograms + 
salmeterol 25 micrograms (120 
actuations) 




Proportion of income 
spent on medicines 
Australia 
 
$4.04 $4.04 $8.08 $15,094.74 0.05% 
Canada – NIHBP $0.00 $0.00 $0.00 $20,795.25 0.00% 
Canada - British 
Columbia 
$0.00 $0.00 $0.00 $9,013.98 0.00% 
Canada - Newfoundland 
and Labrador 
$0.00 $0.00 $0.00 $6,361.17 0.00% 
Canada – Québec 
 
$0.00 $0.00 $0.00 $8,588.50 0.00% 
England 
 
$0.00 $0.00 $0.00 $20,306.72 0.00% 
Finland 
 
$1.03 $12.97 $14 $18,183.62 0.08% 
Germany 
 
$0.00 $0.00 $0.00 Not available 0.00% 
New Zealand 
 
$0.00 $0.00 $0.00 $15,126.46 0.00% 
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Table 18. Patient aged 70 years, on national pension, with type 2 diabetes mellitus, hypertension and hyperlipidaemia. 1-month supply, 
values given in USD PPP for 2015. Doses: Metformin 1 g twice daily + gliclcazide 80 mg once daily OR sitagliptin 100 mg once daily + 
cilazapril 2.5 mg once daily OR perindopril 4 mg once daily OR ramipril 10 mg once daily + atorvastatin 20 mg once daily 























20 mg tablets 










$4.04 $4.04   $4.04  $4.04 $16.15 
 
$15,094.74 0.11% 
Canada – NIHBP $0.00 $0.00    $0.00 $0.00 $0.00 $13,222.99 0.00% 
Canada - British 
Columbia 








$4.58 $4.58    $4.58 $4.58 $18.33 $13,222.99 0.14% 
Canada – Québec 
 
$0.00 $0.00    $0.00 $0.00 $0.00 $13,222.99 0.00% 
England 
 
$0.00  $0.00  $0.00  $0.00 $0.00 $21,849.43 0.00% 
Finland 
 
$3.22  $3.22  $3.73  $8.51 $18.68 $16,118.31 0.12% 
Germany* 
 
$12.84  $12.84   $0.00 $0.00 $25.68 $5315.71 0.48% 
New Zealand 
 
$3.44 $3.44  $3.44   $3.44 $13.75 $15,849.91 0.09% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies.  
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Table 19. Patient aged 70 years, with median income, with type 2 diabetes mellitus, hypertension and hyperlipidaemia. 1-month supply, 
values given in USD PPP for 2015. Doses: Doses: Metformin 1 g twice daily + gliclcazide 80 mg once daily OR sitagliptin 100 mg once daily + 
cilazapril 2.5 mg once daily OR perindopril 4 mg once daily OR ramipril 10 mg once daily + atorvastatin 20 mg once daily 



































$4.04 $4.04   $4.04  $4.04 $16.15 
 
$12,047.20 0.13% 
Canada – NIHBP 
 
$0.00 $0.00    $0.00 $0.00 $0.00 $21,284.87 0.00% 
Canada - British 
Columbia 




$4.58 $4.58    $4.58 $4.58 $18.33 $16,116.80 0.11% 






$0.00  $0.00  $0.00  $0.00 $0.00 $38,251.41 0.00% 
Finland 
 










$3.44 $3.44  $3.44   $3.44 $13.75 $15,397.37 0.09% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies.  
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Table 20. Patient aged 35 years, working 30 hours earning minimum wage, with type 2 diabetes mellitus, hypertension and hyperlipidaemia. 
1-month supply, values given in USD PPP for 2015. Doses: Metformin 1 g twice daily + gliclcazide 80 mg once daily OR sitagliptin 100 mg 
once daily + cilazapril 2.5 mg once daily OR perindopril 4 mg once daily OR ramipril 10 mg once daily + atorvastatin 20 mg once daily 
        Medicine 
               /cost  
 
Country 




























































$0.00  $0.00  $0.00  $0.00 $0.00 $13,843.14 0.00% 
Finland 
 











$3.44 $3.44  $3.44   $3.44 $13.75 $15,816.67 0.09% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies.  
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Table 21. Patient aged 35 years, median individual income, with type 2 diabetes mellitus, hypertension and hyperlipidaemia. 1-month supply, 
values given in USD PPP for 2015. Doses: Metformin 1 g twice daily + gliclcazide 80 mg once daily OR sitagliptin 100 mg once daily + 
cilazapril 2.5 mg once daily OR perindopril 4 mg once daily OR ramipril 10 mg once daily + atorvastatin 20 mg once daily 




































$13.96 $14.38   $13.60  $14.45 $56.40 $29,257.48 0.19% 
Canada – NIHBP 
 
$0.00 $0.00    $0.00 $0.00 $0.00 $20,795.25 0.00% 
Canada - British 
Columbia 




$15.13 $13.02    $15.35 $20.49 $63.99 $35,823.60 0.18% 






$0.00  $0.00  $0.00  $0.00 $0.00 $35,495.23 0.00% 
Finland 
 
$3.22  $3.22  $3.73  $8.51 $18.68 $38,176.31 0.05% 
Germany* 
 





$3.44 $3.44  $3.44   $3.44 $13.75 $23,096.05 0.06% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 




Table 22. Patient aged 35 years, unemployed, receives a benefit/welfare payment, with type 2 diabetes mellitus, hypertension and 
hyperlipidaemia. 1-month supply, values given in USD PPP for 2015. Doses: Metformin 1 g twice daily + gliclcazide 80 mg once daily OR 
sitagliptin 100 mg once daily + cilazapril 2.5 mg once daily OR perindopril 4 mg once daily OR ramipril 10 mg once daily + atorvastatin 20 
mg once daily 



































$4.04 $4.04   $4.04  $4.04 $16.15 
 
$9,099.07 0.18% 
Canada – NIHBP 
 
$0.00 $0.00    $0.00 $0.00 $0.00 $20,795.25 0.00% 
Canada - British 
Columbia 




$0.00 $0.00    $0.00 $0.00 $0.00 $4,894.62 0.00% 






$0.00  $0.00  $0.00  $0.00 $0.00 $10,069 0.00% 
Finland 
 
$3.22  $3.22  $3.73  $8.51 $18.68 $9,122.97 0.20% 
Germany* 
 
$12.84  $12.84   $0.00 $0.00 $25.68 $5,315.71 0.48% 
New Zealand 
 
$3.44 $3.44  $3.44   $3.44 $13.75 $10,751.05 0.13% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 




Table 23. Patient aged 35 years, receives an invalid or sickness benefit (living in the community), with type 2 diabetes mellitus, hypertension 
and hyperlipidaemia. 1-month supply, values given in USD PPP for 2015. Doses: Metformin 1 g twice daily + gliclcazide 80 mg once daily OR 
sitagliptin 100 mg once daily + cilazapril 2.5 mg once daily OR perindopril 4 mg once daily OR ramipril 10 mg once daily + atorvastatin 20 
mg once daily 



































$4.04 $4.04   $4.04  $4.04 $16.15 
 
$15,094.74 0.11% 
Canada – NIHBP 
 
$0.00 $0.00    $0.00 $0.00 $0.00 $20,795.25 0.00% 
Canada - British 
Columbia 




$0.00 $0.00    $0.00 $0.00 $0.00 $4,894.62 0.00% 






$0.00  $0.00  $0.00  $0.00 $0.00 $14,974.42 0.00% 
Finland 
 
$3.22  $3.22  $3.73  $8.51 $18.68 $16,118.31 0.12% 
Germany* 
 
$12.84  $12.84   $0 $0 $25.68 $5,315.71 0.48% 
New Zealand 
 
$3.44 $3.44  $3.44   $3.44 $13.75 $15,126.46 0.09% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 




Table 24. Patient aged 20 years, student receiving government support, with type 2 diabetes mellitus, hypertension and hyperlipidaemia. 1-
month supply, values given in USD PPP for 2015. Doses: Metformin 1 g twice daily + gliclcazide 80 mg once daily OR sitagliptin 100 mg once 
daily + cilazapril 2.5 mg once daily OR perindopril 4 mg once daily OR ramipril 10 mg once daily + atorvastatin 20 mg once daily 























20 mg tablets 










$4.04 $4.04   $4.04  $4.04 $16.15 
 
$7,529.50 0.21% 
Canada – NIHBP 
 
$0.00 $0.00    $0.00 $0.00 $0.00 $2,291.49 0.00% 
Canada - British 
Columbia 



















$0.00  $0.00  $0.00  $0.00 $0.00 $14,174 0.00% 
Finland 
 
$3.22  $3.22  $3.73  $8.51 $18.68 $6,936.41 0.27% 
Germany* 
 





$3.44 $3.44  $3.44   $3.44 $13.75 $6,992.94 0.19% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies.  
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Table 25. Patient aged 20 years, median income, with type 2 diabetes mellitus, hypertension and hyperlipidaemia. 1-month supply, values 
given in USD PPP for 2015. Doses: Metformin 1 g twice daily + gliclcazide 80 mg once daily OR sitagliptin 100 mg once daily + cilazapril 2.5 
mg once daily OR perindopril 4 mg once daily OR ramipril 10 mg once daily + atorvastatin 20 mg once daily 



































$4.04 $4.04   $4.04  $4.04 $16.15 
 
$12,047.20 0.13% 
Canada – NIHBP 
 
$0.00 $0.00    $0.00 $0.00 $0.00 $7,791.06 0.00% 
Canada - British 
Columbia 



















$0.00  $0.00  $0.00  $0.00 $0.00 $37,354.76 0.00% 
Finland 
 










$3.44 $3.44  $3.44   $3.44 $13.75 $6,736.35 0.2% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies.  
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Table 26. Patient aged 70 years, on national pension, with schizophrenia. 1-month supply, values given in USD PPP for 2015. Doses: First-
line: risperidone 4 mg once daily OR olanzapine 10 mg once daily; second-line: clozapine 400 mg daily 










100 mg tablets 























4 mg tablets 
Olanzapine  
10 mg tablets 
Australia 
 
$4.04  $4.04 $4.04 $4.04 $15,094.74 0.03% 0.03% 
Canada – NIHBP $0.00  $0.00 $0.00 $0.00 $13,222.99 0.00% 0.00% 
Canada - British 
Columbia 










$4.58  $4.58 $4.58 $4.58 $13,222.99 0.04% 0.04% 
Canada - Québec $0.00  $0.00 $0.00 $0.00 $13,222.99 0% 0.00% 
England 
 
$0.00  $0.00 $0.00 $0.00 $21,849.43 0% 0.00% 
Finland 
 
 $3.22 $3.22 $3.22 $3.22 $16,118.31 0.02% 0.02% 
Germany* 
 
$0.00  $0.00 $0.00 $0.00 $5315.71 0% 0.00% 
New Zealand 
 
$3.44  $3.44 $3.44 $3.44 $15,849.91 0.02% 0.02% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies.  
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Table 27. Patient aged 70 years, with median income, with schizophrenia. 1-month supply, values given in USD PPP for 2015. Doses: First-
line: risperidone 4 mg once daily OR olanzapine 10 mg once daily; second-line: clozapine 400 mg daily 





or Province  




























4 mg tablets 
Olanzapine  
10 mg tablets 
Australia 
 
$4.04  $4.04 $4.04 $4.04 $12,047.20 0.03% 0.03% 
Canada – NIHBP $0.00  $0.00 $0.00 $0.00 $21,284.87 0.00% 0.00% 
Canada - British 
Columbia 




$4.58  $4.58 $4.58 $4.58 $16,116.80 0.03% 0.03% 






$17,797.22 0.13% 0.38% 
England 
 
$0.00  $0.00 $0.00 $0.00 $38,251.41 0.00% 0.00% 
Finland 
 










$3.44  $3.44 $3.44 $3.44 $15,397.37 0.02% 0.02% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies.  
71 
 
Table 28. Patient aged 35 years, working 30 hours earning minimum wage, with schizophrenia. 1-month supply, values given in USD PPP for 
2015. Doses: First-line: risperidone 4 mg once daily OR olanzapine 10 mg once daily; second-line: clozapine 400 mg daily 





or Province  

































$24.95  $24.95 $24.95 $24.95 $17,853.94 0.13% 0.13% 
Canada – NIHBP $0.00  $0.00 $0.00 $0.00 $12,451.95 0.00% 0.00% 
Canada - British 
Columbia 














$12,213.63 0.07% 0.45% 






$12,511.52 0.18% 0.54% 
England 
 
$0.00  $0.00 $0.00 $0.00 $13,843.14 0.00% 0.00% 
Finland 
 










$3.44  $3.44 $3.44 $3.44 $15,816.67 0.02% 0.02% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies.  
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Table 29. Patient aged 35 years, median individual income, with schizophrenia. 1-month supply, values given in USD PPP for 2015. Doses: 
First-line: risperidone 4 mg once daily OR olanzapine 10 mg once daily; second-line: clozapine 400 mg daily 





or Province  




























4 mg tablets 
Olanzapine  
10 mg tablets 
Australia 
 
$24.95  $24.95 $24.95 $24.95 $29,257.48 0.09% 0.09% 
Canada – NIHBP $0.00  $0.00 $0.00 $0.00 $20,795.25 0% 0.00% 
Canada - British 
Columbia 




$42.00  $273.66 $42.00 $273.66 $35,823.60 0.12% 0.76% 





$32,691.89 0.07% 0.21% 
England 
 
$10.86  $10.86 $10.86 $10.86 $35,495.23 0.03% 0.03% 
Finland 
 
 $3.22 $3.22 $3.22 $3.22 $38,176.31 0.01% 0.01% 
Germany* 
 





$3.44  $3.44 $3.44 $3.44 $23,096.05 0.01% 0.01% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies.  
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Table 30. Patient aged 35 years, unemployed, receives a benefit/welfare payment, with schizophrenia. 1-month supply, values given in USD 
PPP for 2015. Doses: First-line: risperidone 4 mg once daily OR olanzapine 10 mg once daily; second-line: clozapine 400 mg daily 





or Province  


































$4.04  $4.04 $4.04 $4.04 $9,099.07 0.04% 0.04% 
Canada – NIHBP $0.00  $0.00 $0.00 $0.00 $20,795.25 0.00% 0.00% 
Canada - British 
Columbia 




$0.00  $0.00 $0.00 $0.00 $4,894.62 0.00% 0.00% 





$5,646.22 0.40% 1.19% 
England 
 
$0.00  $0.00 $0.00 $0.00 $10,069 0.00% 0.00% 
Finland 
 
 $3.22 $3.22 $3.22 $3.22 $9,122.97 0.04% 0.04% 
Germany* 
 
$0.00  $0.00 $0.00 $0.00 $5,315.71 0.00% 0.00% 
New Zealand 
 
$3.44  $3.44 $3.44 $3.44 $10,751.05 0.03% 0.03% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies.  
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Table 31. Patient aged 35 years, receives an invalid or sickness benefit (living in the community), with schizophrenia. 1-month supply, values 
given in USD PPP for 2015. Doses: First-line: risperidone 4 mg once daily OR olanzapine 10 mg once daily; second-line: clozapine 400 mg 
daily 





or Province  


































$4.04  $4.04 $4.04 $4.04 $15,094.74 0.03% 0.03% 
Canada – NIHBP $0.00  $0.00 $0.00 $0.00 $20,795.25 0.00% 0.00% 
Canada - British 
Columbia 




$0.00  $0.00 $0.00 $0.00 $4,894.62 0.00% 0.00% 





$8,588.50 0.27% 0.78% 
England 
 
$0.00  $0.00 $0.00 $0.00 $14,974.42 0.00% 0.00% 
Finland 
 
 $3.22 $3.22 $3.22 $3.22 $16,118.31 0.02% 0.02% 
Germany* 
 
$0.00  $0.00 $0.00 $0.00 $5,315.71 0.00% 0.00% 
New Zealand 
 
$3.44  $3.44 $3.44 $3.44 $15,126.46 0.02% 0.02% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies.  
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Table 32. Patient aged 20 years, student receiving government support, with schizophrenia. 1-month supply, values given in USD PPP for 
2015. Doses: First-line: risperidone 4 mg once daily OR olanzapine 10 mg once daily; second-line: clozapine 400 mg daily 





or Province  
First-line treatment Second-line 
treatment 
Clozapine  
100 mg tablets 


























10 mg tablets 
Australia 
 
$4.04  $4.04 $4.04 $4.04 $7,529.50 0.05% 0.05% 
Canada – NIHBP $0.00  $0.00 $0.00 $0.00 $2,291.49 0.00% 0.00% 
Canada - British 
Columbia 












$2,291.49 0.37% 2.39% 





$2,291.49 0.99% 2.93% 
England 
 
$0.00  $0.00 $0.00 $0.00 $14,174 0.00% 0.00% 
Finland 
 
 $3.22 $3.22 $3.22 $3.22 $6,936.41 0.05% 0.05% 
Germany* 
 





$3.44  $3.44 $3.44 $3.44 $6,992.94 0.05% 0.05% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies. 
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Table 33. Patient aged 20 years, median income, with schizophrenia. 1-month supply, values given in USD PPP for 2015. Doses: First-line: 
risperidone 4 mg once daily OR olanzapine 10 mg once daily; second-line: clozapine 400 mg daily 





or Province  




























4 mg tablets 
Olanzapine  
10 mg tablets 
Australia 
 
$4.04  $4.04 $4.04 $4.04 $12,047.20 0.03% 0.03% 
Canada – NIHBP $0.00  $0.00 $0.00 $0.00 $7,791.06 0.00% 0.00% 
Canada - British 
Columbia 














$9,089.56 0.09% 0.60% 





$8,096.59 0.28% 0.83% 
England 
 
$0.00  $0.00 $0.00 $0.00 $37,354.76 0.00% 0.00% 
Finland 
 










$3.44  $3.44 $3.44 $3.44 $12,047.20 0.03% 0.03% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 
to $12.84 USD using 2015 PPPs), where a co-payment applies. 
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Table 34. Patient aged 70 years, on national pension, with metastatic renal cell carcinoma. 28-day supply, values given in USD PPP for 2015. 
Dose: sunitinib 50 mg daily for 4 weeks 




Sunitinib 50 mg capsule Total spent on prescription Annual gross income 




$4.04 $4.04 $15,094.74 0.03% 
Canada – NIHBP $0.00 $0.00 $13,222.99 0.00% 
Canada - British Columbia $0.00 $0.00 $13,222.99 0.00% 
Canada - Newfoundland and Labrador $4.58 $4.58 $13,222.99 0.03% 
Canada - Québec $0.00 $0.00 $13,222.99 0.00% 
England 
 
$0.00 $0.00 $21,849.43 0.00% 
Finland 
 
$3.22 $3.22 $16,118.31 0.02% 
Germany* 
 
$12.84 $12.84 $5315.71 0.24% 
New Zealand 
 
$3.44 $3.44 $15,849.91 0.02% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 





Table 35. Patient aged 70 years, with median income, with metastatic renal cell carcinoma. 28-day supply, values given in USD PPP for 2015. 
Dose: sunitinib 50 mg daily for 4 weeks 




Sunitinib 50 mg 
capsule 
Total spent on prescription 
Annual gross 
income 




$4.04 $4.04 $12,047.20 0.03% 
Canada – NIHBP $0.00 $0.00 $21,284.87 0.00% 
Canada - British Columbia $0.00 $0.00 $20,700 0.00% 
Canada - Newfoundland and 
Labrador 
$4.58 $4.58 $16,116.80 0.03% 






$0.00 $0.00 $38,251.41 0.00% 
Finland 
 
$3.22 $3.22 Not available Unknown 
Germany* 
 
$12.84 $12.84 Not available Unknown 
New Zealand 
 
$3.44 $3.44 $15,397.37 0.02% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 





Table 36. Patient aged 35 years, working 30 hours earning minimum wage, with metastatic renal cell carcinoma. 28-day supply, values given 
in USD PPP for 2015. Dose: sunitinib 50 mg daily for 4 weeks 




Sunitinib 50 mg 
capsule 
Total spent on prescription Annual gross income 




$24.95 $24.95 $17,853.94 0.13% 
Canada – NIHBP $0.00 $0.00 $12,451.95 0.00% 
Canada - British Columbia $0.00 $0.00 $12,451.95 0.00% 
Canada - Newfoundland and 
Labrador 
$5,989.75 $1197.95 (Patient contributes 
20%) 
$12,213.63 9.81% 






$0.00 $0.00 $13,843.14 0.00% 
Finland 
 










$3.44 $3.44 $15,816.67 0.02% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 





Table 37. Patient aged 35 years, median individual income, with metastatic renal cell carcinoma. 28-day supply, values given in USD PPP for 
2015. Dose: sunitinib 50 mg daily for 4 weeks 




Sunitinib 50 mg 
capsule 
Total spent on prescription 
Annual gross 
income 




$24.95 $24.95 $29,257.48 0.09% 
Canada – NIHBP $0.00 $0.00 $20,795.25 0.00% 
Canada - British Columbia $0.00 $0.00 $36,663.81 0.00% 
Canada - Newfoundland and 
Labrador 
$5,989.75 $5,989.75 $35,823.60 16.72% 






$0.00 $0.00 $35,495.23 0.00% 
Finland 
 
$3.22 $3.22 $38,176.31 0.01% 
Germany* 
 
$12.84 $12.84 Not available Unknown 
New Zealand 
 
$3.44 $3.44 $23,096.05 0.01% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 




Table 38. Patient aged 35 years, unemployed, receives a benefit/welfare payment, with metastatic renal cell carcinoma. 28-day supply, 
values given in USD PPP for 2015. Dose: sunitinib 50 mg daily for 4 weeks 
                                         Medicine/cost  
 
Country 
or Province  
Sunitinib 50 mg capsule Total spent on prescription Annual gross income 




$4.04 $4.04 $9,099.07 0.04% 
Canada – NIHBP $0.00 $0.00 $20,795.25 0.00% 
Canada - British Columbia $0.00 $0.00 $5,591.23 0.00% 
Canada - Newfoundland and Labrador $0.00 $0.00 $4,894.62 0.00% 
Canada - Québec $1,853.49 $67.03 




$0.00 $0.00 $10,069 0.00% 
Finland 
 
$3.22 $3.22 $9,122.97 0.04% 
Germany* 
 
$12.84 $12.84 $5,315.71 0.24% 
New Zealand 
 
$3.44 $3.44 $10,751.05 0.03% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment 





Table 39. Patient aged 35 years, receives an invalid or sickness benefit (living in the community), with metastatic renal cell carcinoma. 28-
day supply, values given in USD PPP for 2015. Dose: sunitinib 50 mg daily for 4 weeks 




Sunitinib 50 mg capsule Total spent on prescription Annual gross income 




$4.04 $4.04 $15,094.74 0.03% 
Canada – NIHBP $0.00 $0.00 $20,795.25 0.00% 
Canada - British Columbia $0.00 $0.00 $9,013.98 0.00% 
Canada - Newfoundland and Labrador $0.00 $0.00 $4,894.62 0.00% 
Canada - Québec $1,853.49 $67.03 




$0.00 $0.00 $14,974.42 0.00% 
Finland 
 
$3.22 $3.22 $16,118.31 0.02% 
Germany* 
 
$12.84 $12.84 $5,315.71 0.24% 
New Zealand 
 
$3.44 $3.44 $15,126.46 0.02% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment 





Table 40. Patient aged 20 years, student receiving government support, with metastatic renal cell carcinoma. 28-day supply, values given in 
USD PPP for 2015. Dose: sunitinib 50 mg daily for 4 weeks 




Sunitinib 50 mg capsule Total spent on prescription Annual gross income 




$4.04 $4.04 $7,529.50 0.05% 
Canada – NIHBP $0.00 $0.00 $2,291.49 0.00% 
Canada - British Columbia $0.00 $0.00 $2,291.49 0.00% 
Canada - Newfoundland and Labrador $5,989.75 $1197.95 (Patient contributes 
20%) 
$2,291.49 52.28% 
Canada - Québec $1,853.49 $67.03 




$0.00 $0.00 $14,174 0.00% 
Finland 
 
$3.22 $3.22 $6,936.41 0.05% 
Germany* 
 
$12.84 $12.84 Not available Unknown 
New Zealand 
 
$3.44 $3.44 $6,992.94 0.05% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment 





Table 41. Patient aged 20 years, median income, with metastatic renal cell carcinoma. 28-day supply, values given in USD PPP for 2015. 
Dose: sunitinib 50 mg daily for 4 weeks 




Sunitinib 50 mg capsule Total spent on prescription Annual gross income 




$4.04 $4.04 $12,047.20 0.03% 
Canada – NIHBP $0.00 $0.00 $7,791.06 0.00% 
Canada - British Columbia $0.00 $0.00 $6,798.08 0.00% 
Canada - Newfoundland and Labrador $5,989.75 $1197.95 (Patient contributes 20%) $9,089.56 13.18% 
Canada - Québec $1,853.49 $67.03 




$0.00 $0.00 $37,354.76 0.00% 
Finland 
 
$3.22 $3.22 Not available Unknown 
Germany* 
 
$12.84 $12.84 Not available Unknown 
New Zealand 
 
$3.44 $3.44 $6,736.35 0.05% 
*As specific pricing information for Germany was not obtained for all medicines, prices for Germany are estimated at €10, the highest co-payment level (converted 










Australia Canada – 








Québec England Finland Germany New 
Zealand 
Mean  0.095 0.980 0.000 0.434 2.843 0.642 0.003 0.079 0.141 0.052 
Median 0.070 0.200 0.000 0.130 0.130 0.410 0.000 0.050 0.040 0.040 








The results show great variation across the countries/provinces included in the 
study. This is seen in how much countries pay for medicines and how much 
patients spend on out-of-pocket (OOP) prescription charges. The model patients 
who spend the largest proportion of income on prescription medicines were 
generally those on the lowest incomes, particularly young people and those 
earning a minimum wage. The co-payment systems for prescription charges used 
in each country have advantages and disadvantages for both the patient and 
funder. This is the first study to attempt comparison of prescription charges across 
multiple countries for patients with different medical conditions and types of 
income. There are several limitations to this study, key of which is that real patient 
data was not used, and that some data (particularly for Germany) is missing. 
 
Countries paying the highest prices for medicines 
Canada and Australia spend the largest proportion of GDP on medicines, as shown 
in Table 1. This is reflected in the per dose unit prices for the medicines included in 
this study in Table 6. To some extent, these costs are passed on to patients. Canada 
has the highest overall proportion of prescription charges passed on to patients. 
This was particularly seen in the model patient of 20-year-old student on sunitinib, 
as shown in Table 40. New Zealand has the lowest per dose unit prices on all 
medicines with the exception of sunitinib, where New Zealand paid the most per 
dose unit, seen in Table 6.  
Canada has been shown previously to spend more than other countries on 
medicines.(112) This may be due in part to the many purchasers of medicines in 
Canada. This study examined four of the public drug plans. In Canada, there are 
other federal plans and many private plans also available.(198) With the exception 
of Germany, the other countries in this study all have a single public agency 
responsible for the purchasing medicines or setting medicine prices.(31, 38, 57, 77, 
151, 198) This gives these agencies greater bargaining power, especially as they 
are responsible for larger populations than the Canadian plans. 
In this study, all of the six countries used generic medicines where available, which 
could be expected to reduce medicine prices.(9) However, the list prices in New 
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Zealand are considerably lower than any of the other countries (see Table 6). The 
Pharmaceutical Management Agency of New Zealand (PHARMAC) prefers to use 
cheaper generic medicines where possible and combines this with using reference 
pricing and tendering processes to contain the cost of medicines. The prices in 
Table 6 show that PHARMAC appears to combine these strategies to great effect in 
reducing medicine costs. This is despite the relatively small population of New 
Zealand; it is the smallest country by population included in the study. 
 
Countries where patients spend the greatest proportion on prescription charges 
Given the higher prices Canada pays for medicines, it is not surprising to find that 
patients in Canada spend more of their income on prescription charges. The mean 
proportion of income spent on medicines across all of the scenarios in Canada was 
0.98% as shown in Table 42. Within Canada, patients in Newfoundland and 
Labrador face the highest costs, with a mean proportion of 2.84% (see Table 42) 
across all scenarios. This was particularly due to the prescription charges 
associated with sunitinib, the most expensive drug in the study. This may be due to 
the Newfoundland and Labrador Prescription Drug Plan (NLPDP) having a small 
population that it covers, as well as being a payer of “last resort”.(43)  
In Table 42, German patients had the second highest proportion of income spent, 
however, the mean and median information in the tables are based on incomplete 
data on patient incomes. Patients in England paid the lowest proportion of incomes 
on medicines, where all but two of the model patients would be exempt from 
prescription charges. The New Zealand model patients paid the second lowest 
proportion of income on medicines, despite only three of the model patients 
receiving prescriptions free of charge. 
 
Patients at risk of spending the greatest proportion of income on prescription 
charges 
In Tables 6-40, patients aged 20 years were the most at risk of high prescription 
costs. At this age, many young people are either studying or earning relatively low 
incomes as they enter the workforce.(199) The median incomes for a 20-year-old 
may not be entirely reflective of for the non-studying part of the population, as 
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those earning in the 20-year-old population will have higher incomes than 
students. There may also be some students with no income. England was the only 
country to exempt these patients from prescription charges and this was based on 
level of income. In Australia, these 20-year-old model patients would also have had 
a lower prescription charge based on their level of income, as they would be 
eligible for a concession card. 
People earning a minimum wage were the next group most likely to spend a higher 
proportion of income on prescription charges. While some in this group have 
access to lower prescription prices due to level of income (such as in Australia and 
England), this was not as consistent as with patients receiving government 
benefits. Many of the patients on benefits would be entitled to lower prescription 
charges or free prescriptions. 
Model patients with metastatic renal cell carcinoma (RCC) faced the highest 
prescription costs of all the medical conditions. This was mostly due to the high 
cost of the medicine being passed on to the patient in systems with a variable co-
payment (Newfoundland and Labrador and Québec). In the past, most cancer 
treatments were given in hospital(200) and in the countries in this study, all 
medicines given in hospital are given free of charge.(8) As many new cancer 
medicines are oral medicines, patients are able to take these at home. The potential 
disadvantage of this will be if they must collect a prescription for their medicine 
and be faced with a substantial prescription charge. If cancer medicines and other 
medicines of similar value are not available free of charge or at a lower charge, 
these expensive medicines could cause major financial hardship for some patients.  
The medicines used in the treatment of schizophrenia were also found to be 
expensive in this study. As people with mental illness often struggle with 
employment,(201) they may potentially have lower incomes than the model 
patients used in this study. The price of medicines for the treatment of 
schizophrenia may therefore be another barrier to treatment for an already 
vulnerable group. 
Most of the model patient scenarios were for a single person. However, many 
people live with their families. The family patient scenario included was for the 
prescription charges for an asthmatic child, which are presumed to be paid for by 
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their parents. If the families had another person with a medical condition, the 
proportion of income spent on medicines would therefore increase.  
 
Commentary on co-payment systems 
The co-payment systems used by the six countries revealed considerable variation 
in what patients pay for prescription charges. Canada’s various systems seem to 
leave people more vulnerable to high prescription costs. While prescription 
charges are lower in other countries, patients may still face significant prescription 
charges proportionate to income, if they are on low incomes. One solution to this is 
to exempt low-income people from prescription charges or charge a lower fee for 
those on low incomes. England, British Columbia and Newfoundland and Labrador 
all charged no prescription fee to patients on benefits. Australia offered a lower 
rate through access to concession cards.(150) Only England exempted low-income 
people from prescription charges. Australia again offered a lower rate to those on a 
low income. Canada, Finland, Germany and New Zealand all charged the same rates 
to low-income patients as high-income patients,(39, 67, 72, 77) with the 
consequence that low-income patients will spend a greater proportion of income 
to treat the same medical conditions. A finding from this study is that the only way 
to protect patients completely from prescription costs is to make them free of 
charge. Prescription medicines were provided free of charge by the Canadian Non-
Insured Health Benefits Program (NIHBP), and for most of the model patients in 
England. For the patient, the second-most affordable alternative is a low fixed co-
payment, as used in New Zealand and for concession-card holders in Australia. 
Deductibles are used as a cost-sharing method by British Columbia and 
Québec.(44, 47) With the model patients receiving their first prescriptions of the 
year in the scenarios, this means the first prescription charge is potentially one of 
the most expensive for the year. Also in these provinces, the first prescription 
charge will include the deductible. Once the deductible is met, the co-payment will 
be reduced, so prescriptions may not be charged at the same rate through the year. 
In 2017, Finland introduced a deductible of €50, which increases patient 
prescription charges at the beginning of the year. This could potentially pose an 
additional barrier to patients with the lowest incomes accessing medicines.  
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Variable co-payments are used for prescription charges in British Columbia, 
Newfoundland and Labrador, Québec and Finland.(43, 44, 47, 67) As Finland has 
lower list prices for medicines, as shown in Table 6, the list prices of the medicines 
did not have as great an impact on the OOP payment. The medicines with the 
highest costs in Finland (olanzapine, clozapine and sunitinib), were also medicines 
that are fully reimbursed and only subject to a €3 co-payment.(67, 68) However, in 
the provinces of Canada, the list prices for medicines are high, therefore the 
amount patients are required to contribute are also high. The affordability of high-
cost medicines under Canadian provincial drug plans currently is low in the model 
patient scenarios, where no exemption from OOP costs exist.  
 
Strengths and limitations 
This study compares the overall cost of the standard treatments of the selected 
medical conditions, in addition to comparing the cost of the individual medicines. 
This is most pertinent for the type 2 diabetes mellitus (T2DM) patient, where the 
standard prescription medicines varied between countries. Where there is 
variation in what medicines a patient may take for the treatment of a medical 
condition, it seems fairer to compare the standard treatment in each country, 
rather than medicines that are unavailable or unlikely to be used. 
This is the first study to compare OOP costs for prescription medicines for a range 
of countries, patients, income type and medical conditions. While other studies 
have compared medicine prices(121-123) or patients’ OOP costs,(136, 137) this 
study demonstrates more practical situations by comparing the proportion of 
income spent on medicines across a range of countries and patient incomes. The 
international collaborators provide in-depth knowledge of the prescription costs in 
each country. This gives the study accurate representations of the local situations, 
as compared with only reporting information from regulatory agencies. Examining 
the proportion of income spent on prescription medicines is useful for policy 
makers to try to set fair prices for co-payment systems. This supports for some 




While no real patient data was used in this study, using model patients gives 
unique insights into how co-payment systems work and the application of such 
systems to real-life situations. It would be difficult to obtain real data for so many 
different types of patients. The advantage of using real patient data is that the 
potential impact of prescription costs on health could be evaluated. 
There was missing data for some of the model patients. Some of the list prices in 
Germany were not able to be obtained as there is no single agency responsible for 
the purchasing or pricing of medicines. The providers of social insurance in 
Germany do not make their list prices public. The Canadian NIHBP keeps all of its 
prices confidential, as does the British Columbia Cancer Agency, so list prices are 
also missing for these medicines(194, 195). 
The 20-year-old model patient with T2DM is an unlikely scenario clinically, as 
T2DM usually develops later in adulthood.(90) However, as T2DM incidence is 
rising in young people the scenario was included in the study, as it may have future 
implications. 
Many patients have more than one medical condition requiring concomitant 
treatment with medicines. If real patient data could be used, it would more 
accurately give the proportion of income spent on prescription medicines, rather 
than just one medical condition at a time. This is particularly true if family or 
household data could be collected, as the members of a family may have multiple 
medical conditions.  
The model patient incomes given in Table 4 are best estimates for the income 
types. They originate from a range of years (2010-2015) depending on the 
source.(149, 160-170) Where census data was used, the last census may have been 
as long ago as 2010. Newer census data may still be under review by the statistics 
agency and not yet reported publicly. Census data may also be reliant on 
participants self-reporting on areas such as income, which may not have been 
accurate. For example, people may have reported their net (after-tax) income 
instead of their gross (before-tax) income. Therefore, this may explain why some 
of the median incomes were less than that of patients receiving benefits or 
pensions, who were expected to be the minimum income. The drug list prices and 
co-payments were all for 2015-2016,(34, 78, 188-193) and income from before 
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2015-2016 may be lower due to inflation rates. This means that the proportion of 
income spent may be overestimated for some of the model patients. 
The model patients received one month’s supply of medicines in each of the 
scenarios. Australia and Canada standardly give one month’s supply of medicines 
per prescription.(34, 202) In England, Finland, Germany and New Zealand, 
prescriptions are usually given for three month’s supply, though a one-month 
supply is possible.(61, 67, 78, 197) If the proportion of income spent on medicines 
over one year was to be investigated, it would be expected that patients supplied 
three months’ medicine at a time would have lower costs than those patients only 
supplied one month at a time.   
The NIHBP in Canada provides prescription medicines free of charge to indigenous 
people.(39) In Australia and New Zealand there are some local organisations that 
aid indigenous people with prescription costs, but no national schemes. Because of 
the lack of national schemes, indigenous people from Australia and New Zealand 
were not examined separately in the study. However, indigenous people from 
Australia and New Zealand were not excluded from the general population data 
used in the study. 
 
Implications for further research 
The estimates of proportion of income spent on prescription medicines given in 
this study provide a good starting point for further research. To use real patient 
prescription and income data could create a better picture of what patients spend 
on prescription medicines. There is very limited information on whether 
prescription charges have any impact on patient health outcomes. A study with an 







Patient out-of-pocket prescription medicine costs vary widely between different 
countries, co-payment systems, patient income levels and medical conditions. As a 
proportion of patient income, medicine costs can be very high for some patients 
carrying implications for affordability.  
Using a set of model patients across six countries with nine different co-payment 
systems was a practical way to compare prices of medicines and the proportion of 
income patients spend on medicines. Of the countries included in the study, the list 
prices of prescription medicines were highest in Canada and lowest in New 
Zealand. Patients spent the least amount of income on prescription medicines in 
England and New Zealand, while patients in Canada spent the most.  
Of the different patients included in the study, younger patients with lower income 
levels were most vulnerable to prescription costs. Some countries offered reduced 
prescription charges or exemptions to certain groups of patients or for particular 
medical conditions, which eased the financial burden. 
The study was somewhat limited by missing data for some countries, which would 
have created better estimates of what patients really spend on medicines. Further 
research using real patient data should be considered and this may reveal the 
impact of prescription charges on patient health. This is the first study to compare 
prescription charges as a proportion of patient income across a range of countries, 
patient income types and medical conditions. 
Affordability of prescription medicines, both nationally and on an individual 
patient level, is an important issue. This study contributes a new perspective and 
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